Curriculum Vitae

Medical Education

• 1967–1973 Medical education in Madrid, Spain, and at Universidad de la República, Montevideo, Uruguay. MD, 1973.

Postgraduate Training

• 1974 - 1977 Residency in Internal Medicine, Thomas Jefferson University Hospital of Thomas Jefferson University, Philadelphia, Pennsylvania
• 1977 - 1978 Fellowship in Internal Medicine, Thomas Jefferson University Hospital of Thomas Jefferson University, Philadelphia, Pennsylvania
• 1978 - 1981 Fellowship in Endocrinology and Metabolism, Strong Memorial Hospital, University of Rochester School of Medicine and Dentistry, Rochester, New York

Certifications

• 1979 Board Certification in Internal Medicine, American Board of Internal Medicine
• 1984 Board Certification in Endocrinology and Metabolism, American Board of Internal Medicine

Appointments

• 1981 - 1983 Assistant Professor of Medicine, Endocrinology and Metabolism, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
• 1983 - 1986 Associate Professor of Medicine, Section Head of Endocrinology and Metabolism, East Carolina University School of Medicine, Greenville, North Carolina
• 1986 - 1991 Professor of Medicine, Section Head of Endocrinology and Metabolism and Director of the University Diabetes Center, East Carolina University School of Medicine, Greenville, North Carolina
• 1991 - 1996 Magee Professor of Medicine and Chairman of the Department, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
• 1996 - 2008 Vice President, Endocrine Research and Clinical Investigation and Vice President of Global Diabetes Care. Lilly Research Laboratories, Eli Lilly & Comp, Lilly Corporate Center, Indianapolis, IN
• 1996 - 2008 Professor of Medicine, Indiana University School of Medicine, Indianapolis, IN
• 2005 - the archived CV Distinguished Professor of Medicine, Emeritus, East Carolina University School of Medicine, Greenville, NC
• 2007 – the archived CV Co-Founder, Chief Scientific Officer Emeritus and Honorary Member of the Executive Committee of Peers for Progress. AAFP, University of North Carolina, Chapel Hill, NC
• 2012 onward (archived CV) President and Founder, JFC Solutions LLC
• 2009 Associate Dean for Clinical Investigation, Brody School of Medicine, East Carolina University.

Awards And Research Grants ( Direct Cost Only)

• 1979 - 1981 Juvenile Diabetes Foundation Fellowship Award (P.I.)
• 1981 - 1983 American Diabetes Association Wayne Newton Research Grant (P.I.)
• 1981 - 1982 Small Grant Award PHS Biomedical Research Support Grant 5 S07 RR0514, Jefferson Medical College (P.I.)
• 1981 - 1982 Department of Medicine Research Grant, Jefferson Medical College (P.I.)
• 1981 - 1983 Juvenile Diabetes Foundation Research Grant (P.I.)
• 1982 - 1983 Research Grant, Upjohn Company (P.I.)
• 1982 - 1985 New Investigator Research Award 1 R23AM 30558, National Institutes of Health (PI)
• 1984 - 1985 Research Grant, 5-81011 Years Laboratories (P.I.)
• 1985 - 1987 Research Grant, Upjohn Company (P.I.)
• 1985 - 1988 Research Grant, R01-AM 32585 National Institutes of Health (P.I.)
• 1986 - 1990 Research Grant, R01-DK 38066 National Institutes of Health (P.I.) (This grant was funded but was inactivated because of overlap with Program Project DK 36296
• 1987 - 1988 Sponsor of Fogerty Fellowship Award from the National Institutes of Health (IF05TW04048) to Dr. Ivan Contreras
• 1987 - 1992 ECU Diabetes Program Project, P01-DK 36296 National Institutes of Health (Program Director)
• 1987 - 1992 Research Grant, Eli Lilly Company (P.I.)
• 1988 - 1989 Research Grant, Glaxo Pharmaceutical Company (P.I.)
• 1988 - 1989 Research Grant, R03-DK 41191-1 National Institutes of Health (P.I.)
• 1988 - 1989 Research Grant, Pfizer Pharmaceutical Company (P.I.)
• 1989 - 1992 Sponsor of Fellowship Award from the National Institutes of Health (IF32DK08477) to Dr. Jacob Friedman
• 1990 - 1991 Research Grant, Park Davis Pharmaceutical Company (P.I.)
• 1990 Small Grant Award: Roaring Visiting Professorship Program in Diabetes Management
• 1990 Research Grant, 1R03-DK 2924 National Institutes of Health (P.I.)
• 1990 - 1992 Research Grant, Amylin Pharmaceutical Company (P.I.)
• 1991 - 1993 Sponsor of Fellowship Award to Dr. Bartolome Burguera from the Juvenile Diabetes Foundation
• 1991 - 1992 Research Grant, Hoechst-Roussel Pharmaceuticals, Inc. (P.I.)
• 1992 - 1994 Sponsor of Fellowship Award to Dr. Robert Considine from the National Institutes of Health (IF32DK08888)
• 1993 - 1994 Research Grant, Eli Lilly Company (P.I.)
• 1993 - 1994 Research Grant, Eli Lilly Company (Co-PI)
• 1993 - 1995 Research Grant, Amylin Pharmaceutical, Inc. (P.I.)
• 1994 - 1995 Research Grant, Miles Laboratories (P.I.)
• 1994 - 1995 Research Grant, Pfizer Pharmaceuticals (Co-Invest.)
• 1994 - 1996 Research Grant, CI-991, Park Davis Pharmaceuticals (Co-Invest.)
• 1992–1995 NIH research grant R01DK045592, Thomas Jefferson University.
• 1994 - 2002 Research Grant, UO1-DK48468, National Institutes of Health (P.I.)

Special Research Grants

• BRIDGES, International Diabetes Federation: Caro helped initiate the program through Lilly Foundation support. IDF launched BRIDGES in 2007, following its December 2006 announcement.
• Peers for Progress: Caro helped initiate the program through Lilly Foundation support. The program was founded in 2006; Caro’s involvement began in 2007.

Honors And Named Lectureships

• 1986-1992 Recipient of the “ Pearl Lecturer” every year while in the Faculty (Senior Medical Students' Teaching Award). East Carolina University School of Medicine, Greenville, NC
• 1988 -2012 Member of the American Society of Clinical Investigators (Young Turk)
• 1991 Outstanding Investigator Award. Department of Medicine Fifth Annual Research Day, East Carolina University School of Medicine, Greenville, NC, 1991.
• 1992 Karl Paschkis Lecturer, "NIDDM: Lessons from the Laboratory." The Philadelphia Endocrine Society, Philadelphia, Pennsylvania, 1992.
• 1993 Bernardo A. Houssay Lecturer, "Insulin Resistance in Type II Diabetes", International Diabetes Foundation and The Costa Rican Association of Endocrinology, San Jose, Costa Rica, 1993.
• 1996 Mithoffer Lecturer, "Leptin: The Tale of an Obesity Gene", Medical University of South Carolina, Charleston, SC, 1996.
• 1996 Alexander Marble Lecturer, “Obesity: A syndrome of Leptin Resistance”. Joslin Diabetes Center. Harvard Medical School. Boston, Massachusetts, 1996.
• 1997 Banting and Best Lecturer: [lecture title omitted]. University of Toronto. Canada Diabetes Association. Toronto, Canada, 1997
• 1998 Eugene Furth Lecturer [lecture title omitted] East Carolina University School of Medicine, Greenville, North Carolina, 1998
• 1998 A.M. Cohen Memorial Lecturer: [lecture title omitted]. VII International Symposium on Insulin Receptors and Insulin Action: Molecular and Clinical Aspects. Jerusalem, Israel, 1998
• 1998 Recipient of the Medal of Honor and Honorary Membership to the Real Academy of Medicine of Granada. Granada, Spain, 1998
• Ranked third most-cited author in obesity research, 1991–2000; ISI Essential Science Indicators, December 2001.
• 2000 - 2012 Member of the Association of American Physicians (Old Turk)
• 2004 - present Honorary Director of the Peking Diabetes Center and Honorary Professor of the Peking University Health Science Center. Peking, China.
• 2005 The Leslie Nicholas Lecture “The scientific Basis of New Therapies for Obesity”. The College of Physicians of Philadelphia, PA

Editorial Activities

• 1988 - 1996 Associate Editor, Advances in Diabetologia
• 1991 - 1997 Associate Editor, Diabetes Care
• 1991 - 2002 Editorial Board, Journal of Clinical Endocrinology and Metabolism
• 1992 - 2002 Section Editor, Obesity Research, North American Association for the Study of Obesity
• 1994 - 1999 Associate Editor, Medicina y Cultura
• 1985 - 2008 Associate Editor, Metabolism Clinical and Experimental
• 2001 -2005 Section Editor, Nutrition and Obesity, Endotext.com
• 2004 - 2006 Co-Editor, The Metabolic Syndrome at the Beginning of the XXI Century: A Genetic and Molecular Approach
• 2005 - 2008 Editorial Board, Journal of Clinical Endocrinology and Metabolism
• 2005 – 2008 International Editorial Board, Obesity and Metabolism

Consultant Activities To NIH

• 1985 - 1989 Member, Metabolism Study Section, National Institutes of Arthritis, Diabetes and Kidney Diseases. National Institutes of Health
• 1989 Special Reviewer, Study Section for Small Business Innovation Research, Pharmacology Panel, National Institutes of Health
• 1989 Member, Site Visit Team, General Clinical Research Center Committee. National Institutes of Health
• 1989 Member, Site Visit Team to review a NIH General Clinical Research Center
• 1990 Member, Clinical Sciences Study Section Site Visit. National Institutes of Health
• 1991 Member, NIH Site Visit Team, General Clinical Research Center
• 1992 Member, Special Review Committee, National Institute of General Medical Sciences, NIH
• 1992 Member, External Advisory Committee, Sims' Obesity and Nutrition Research Center, NIDDK and NICHD
• 1992 Member, NIDDK Special Grant Review Committee
• 1992 Chairman, Diabetes Endocrinology Research Center Study Section, NIH, Bethesda, Maryland
• 1992 Member, Site Visit Team, General Clinical Research Center, National Institute of Health
• 1993 Chairman, Ad Hoc Review Group SSS-L Clinical Sciences Review Section, National Institute of Health.
• 1994 Member, Behavioral and Neurosciences Special Emphasis Panel, NIH
• 1995 Member, Ad Hoc Review Committee, Diabetes Research and Training Centers, National Institute of Health
• 1998 Member, Congressionally Mandated Diabetes Research Working Group and Chairman of the Industry/Academia Subgroup, NationalInstitute of Health (NIH).
• 1996 - 2000 Member, Subcommittee B of the Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH
• 2000 - 2004 Member of the National Institute of Digestives and Diabetes and Kidney Diseases Advisory Council, NIH and Chairman of the Concurrence Grant Awards Approval Committee of the NIDDK Advisory Council, NIH
• 2000 – 2004 Member of the Disease Prevention and Management Working Group, Advisory Council of the National Institute of Diabetes and Digestive and Kidney Diseases, NIH
• 2000 – 2004 Member of the Advisory Council Operating Procedures Working Group, NIDDK Advisory Council, NIH

Consultant Activities To The American Diabetes Association

• 1984 - 1985 Chairman, Patient Education Committee, American Diabetes Association, North Carolina
• 1984 - 1985 President, American Diabetes Association, Pitt County Chapter, North Carolina
• 1985 - 1986 Chairman, Patient Education Committee, American Diabetes Association, North Carolina Affiliate
• 1988 - 1991 Member, Professional Education Committee, American Diabetes Association
• 1989-1991 Member, Committee on Scientific and Medical Profession. American Diabetes Association
• 1992 Member, Grant Review Panel, Studies on Genetics in NIDDM, American Diabetes Association, New York, NY.
• 1989-1991 Master Faculty, Clinical Education Program, "Managing Diabetes in the 1990's," American Diabetes Association.
• 1990 - 1991 President Elect, American Diabetes Association, North Carolina Affiliate
• 1991 - 1992 President, American Diabetes Association, North Carolina Affiliate
• 1992 - 1996 Member, Board of Directors, American Diabetes Association, Pennsylvania Affiliate
• 1992 - 1996 Member, Professional Education Committee, American Diabetes Association, Pennsylvania Affiliate
• 1993 Panel member, Consensus Development Conference on the Treatment of Hypertension in Diabetes, American Diabetes Association
• 1993 - 1996 Member of the Academic Steering Committee, Professional Diabetes Academy
• 1994 - 1996 Chairman, Scientific and Medical Meetings Oversight Committee of the American Diabetes Association
• 1994 - 1996 Member, Professional Section Advisory Panel of the American Diabetes Association

Medical School Committees

• 1985 - 1986 Member, Policy and Review Committee on Human Research, East Carolina University
• 1985 - 1986 Member, House Staff Evaluation Committee, East Carolina University
• 1985 - 1991 Member, Human Organ Transplant Committee, East Carolina University
• 1985 - 1991 Member, Department of Medicine Research Advisory Committee, East Carolina University
• 1986 - 1987 Member, Radiation Safety Committee, East Carolina University
• 1986 - 1987 Member, Institutional Review Committee, Pitt County Memorial Hospital
• 1987 - 1988 Member, Dean's Search Committee (Elected by the Faculty), East Carolina University
• 1987 - 1991 Member, Jacob Furth Prize Committee, East Carolina University
• 1989 - 1990 Chairman, Ad Hoc Committee, Clinical Research Center, School of Medicine, East Carolina University
• 1989-1990 Member, Ad Hoc Committee, Medical School Core Laboratory Facilities. School of Medicine, East Carolina University
• 1991 Member, Search Committee for Chairman of the Department of Medicine (Elected by the faculty), East Carolina University
• 1995 - 1996 Member, University Advisory Committee on International Affairs, Thomas Jefferson University
• 1995 - 1996 Secretary, Jefferson Faculty Foundation Executive Committee, Jefferson Medical College
• 1995 Member, Jefferson Faculty Foundation Finance Committee, Jefferson Medical College

Other Consultant/Committee Work

• 1986-1996 Ad Hoc Reviewer, Research Grants Program. Veterans Administration, Washington, DC
• 1988 - 1992 Member of the Medical Science Review Committee, Juvenile Diabetes Foundation International
• 1989-1999 Ad Hoc Reviewer, National Science Foundation. Washington, DC
• 1989-1991 Member, Board of Medical Advisors. Amylin Corporation, San Diego, CA
• 1992 - 1996 Member, Board of Trustees, Methodist Hospital, Philadelphia, PA
• 1992 - 1996 Member, Board of Trustees, Magee Rehabilitation Hospital, Philadelphia, PA
• 1992 - 1996 Member, Board of Directors, Philadelphia Endocrine Society
• 1993 - 1996 Member, Boston Obesity/Nutrition Research Center Scientific Advisory Group
• 1993 - 1994 Member, Education Committee, Professional Diabetes Academy
• 1994 - 1996 Member, Academic Advisory Committee of the Pfizer Visiting Professorship Program in Diabetes Management
• 1994 Member, Committee on Faculty and Researchers, Interamerican College of Physicians and Surgeons
• 2001 - 2005 Member, JDRF Management Advisory Board
• 2004 Member, American Obesity Association Advisory Board

Professional Societies/Memberships

• 1976 -2010 Member, American Society of Internal Medicine
• 1977 -2010 Member, American College of Physicians
• 1979 - 2010 Member, American Federation for Clinical Research
• 1980 - 2010 Member, American Diabetes Association
• 1980 - 2010 Member, Endocrine Society
• 1984 - 2010 Member, American Association for the Advancement of Science
• 1984 - 2010 Member, American Medical Association
• 1984 - 1992 North Carolina Medical Society
• 1988 - 2010 Member, American Society for Clinical Investigation (Young Turk)
• 1991 - 2010 Member, Sigma Xi, The Scientific Research Society
• 1992 - 1997 Pennsylvania Medical Society
• 1992 - 1997 Philadelphia County Medical Society
• 1992 - 1997 College of Physicians of Philadelphia
• 1992 - 2010 Charter Member, American Association of Clinical Endocrinologists
• 1993 - 2010 Fellow, American College of Physicians
• 1993 - 2010 Member, North American Association for the Study of Obesity
• 1993 - 2010 Member, Professional Diabetes Association
• 1995 - 2010 Member, Society of Ibero Latin American Medical Professionals
• 1996 - 1997 Member, American Society for Clinical Pharmacology and Therapeutics
• 2000 - 2010 Member, Association of American Physicians (Old Turk)

Special Post Graduate Education

• 1992 Program for Chiefs of Clinical Services, Harvard School of Public Health
• 1993 Program for Executives in Managed Care, Harvard School of Public Health

Visiting Professorships And Special Lectures

• Invited Speaker. "Mechanism of Insulin Resistance in Uremia." University of Pennsylvania. Philadelphia, PA, 1981
• Invited Speaker. "Insulin Binding and Processing in Isolated Rat Hepatocytes." University of Virginia. Charlottesville, VA, 1981
• Invited Speaker. "Insulin Resistance in Uremia." University of South Florida. Tampa, FL, 1982
• Invited Speaker. "Insulin Resistance in Uremia." Duke University School of Medicine. Durham, NC, 1982
• Program Chairman. "The Diagnoses and Treatment of Type II Diabetes." American Diabetes Association and East Carolina University School of Medicine. Greenville, NC, 1984
• Invited Speaker. "Management of Type II Diabetes." At the "First Congress in Washington, DC of the Interamerican College of Physicians and Surgeons." Washington, DC, 1984
• Invited Speaker. "Mechanism of Insulin Action" and "Hyperlipidemia in Diabetes." The Third Annual Scientific Panel and the University of Zulia. Maracaibo, Venezuela, 1985
• Invited Speaker. "Gastric Bypass: A Human Model to Study Diabetes." Duke University School of Medicine. Durham, NC, 1985
• Visiting Professor. "Mechanism of Insulin Resistance in the Human Liver from Patients with NIDDM." University of Rochester School of Medicine and Dentistry. Rochester, NY, 1986
• Moderator. "Learn by Sharing." Patient Education Program of the American Diabetes Association, North Carolina Affiliate. Raleigh, NC, 1985
• Invited Speaker. "Diabetic Emergencies" and "Office Management of Type II Diabetes." 14th Annual Beach Workshop. Myrtle Beach, SC, 1986
• Invited Speaker. "Insulin Receptor Kinase Activity in Human Liver, Muscle, and Adipose Tissue." Lilly Research Laboratories. Indianapolis, IN, 1986
• Visiting Professor. "ECU Diabetes Program Project." Diabetes Branch of the National Institutes of Health, Bethesda, MD, 1986
• Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Geriatric Research Center, Johns Hopkins University School of Medicine. Baltimore, MD, 1986
• Visiting Professor. "The Mechanism of Insulin Resistance in Type II Diabetes." Department of Pathology, University Complutense School of Medicine. Madrid, Spain, 1986
• Invited Speaker. "The Human Endocrine System: A Brief Review." At the Fourth Annual Biotechnology Symposium." East Carolina University School of Medicine. Greenville, NC, 1986
• Visiting Professor. "Insulin Receptor Kinase in Important Target Tissues for Insulin in Type II Diabetes Mellitus." Department of Medicine, University of Rochester School of Medicine and Dentistry. Rochester, NY, 1987
• Invited Speaker. "The Insulin Receptor and Liver, Skeletal Muscle, and Adipose Tissue from Humans with and without Type II Diabetes." Lilly Diabetes Care International Symposium. Indianapolis, IN, 1987
• Invited Speaker. "Mechanisms of Insulin Resistance in Type II Diabetes." At the "National Institutes of Health Centennial, Nurturing Creative Research Genius for Biomedicine." Duke University School of Medicine. Durham, NC, 1987
• Symposium Chairman. "Diabetes Mellitus: Management in Pregnancy and Childhood." American Diabetes Association and East Carolina University School of Medicine. Greenville, NC, 1987
• Invited Speaker. "Type II Diabetes Mellitus: Treatment and Complications." The XI Interamerican Medical Congress of the Spanish-American Medical Society. New York, NY, 1987
• Visiting Professor. "Mechanisms of Insulin Resistance in Type II Diabetes." University of Virginia Diabetes Center, Charlottesville, VA, 1987
• Visiting Professor. "Role of Insulin Receptor Tyrosine Kinase in Insulin Resistance." Glaxo Research Laboratory. Research Triangle Park, NC, 1987
• Invited Speaker. "Advances in the Treatment of Type II Diabetes." At the XII Annual Conference of the North Carolina Academy of Physicians." Wrightsville, NC, 1988
• Invited Speaker. "Carbohydrate Metabolism in Diabetes." At the "IX Annual Congress of the Spanish Society of Diabetes." Barcelona, Spain, 1988
• Invited Speaker. "Current Views of Etiology of Type II Diabetes: Are We Getting There?" At "Diabetes Update 1988." American Diabetes Association and East Carolina University School of Medicine. Southern Pines, NC, 1988
• Invited Speaker. "The Insulin Receptor in Obesity and NIDDM: A New Target for Clinical and Basic Research." At a symposium on the "Mechanism of Insulin Resistance in Type II Diabetes" 70th Annual Meeting of the Endocrine Society. New Orleans, LA, 1988
• Visiting Professor and Clinical Scholar. Lilly task force on "Early Recognition and Prevention of Diabetes." Lilly Research Laboratories. Indianapolis, IN, 1988
• Invited Speaker. "Diabetic Emergencies." North Carolina Family Physician's Annual Meeting. Wrightsville Beach, NC, 1988
• Invited Speaker. "Diabetes." Geriatric Medicine Board Review. East Carolina University School of Medicine. Greenville, NC, 1988
• Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Veterans Administration Medical Center at Georgetown University. Washington, DC, 1988
• Invited Speaker. "Insulin Receptor Kinase Alterations." At the "Action of Insulin and Related Growth Factors in Diabetes Mellitus." Celebrating Joslin's 90th Anniversary. Joslin Diabetes Center and Harvard Medical School. Boston, MA, 1988
• Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." University of Illinois Chicago, IL, 1988
• Visiting Professor. "Insulin Resistance." University of California, San Diego, CA, 1988
• Invited Speaker. "Devastation of the Disease: Type II Diabetes." Third Hispanic Medical Congress. Washington, DC, 1988
• Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes" and "Chronic Complications of Diabetes." Diabetes Branch of the National Institutes of Health. Bethesda, MD, 1988
• Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes" and "Chronic Complications of Diabetes." University of Colorado Health Sciences Center. Denver, Colorado, 1988
• Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Diabetes Clinical Research Institute, Charlottesville, VA, 1989
• Visiting Professor. "The Insulin Receptor: A New Target For Basic and Clinical Investigations." Research Seminar, Emory University, Atlanta, GA, 1989
• Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Diabetes Center of Eastern Virginia, Norfolk, VA, 1989
• Invited Speaker. "Mechanism of Insulin Action." Inter-University Post-Graduate course on Molecular Mechanism of the Endocrine System, Fundacion Ramon Areces, Madrid, Spain, 1989
• Keynote Speaker. "The Pathogenesis of Obesity" and "Meet the Professor: Problem Case Discussion." At Diabetes Mellitus - Challenges in the 1990's." American Diabetes Association, Hilton Head Island, SC, 1989
• Invited Speaker. "Clinical and Physiological Correlates of Glucose Transport in Obesity and Diabetes" at "The Symposium in Frontiers in the Molecular and Cellular Biology and Glucose Transport." 49th Annual Meeting and Scientific Sessions, American Diabetes Association, 1989
• Invited Speaker. "Insulin Resistance in Obesity: Towards a Molecular Approach." UCLA Symposium on Molecular and Cellular Biology, Keystone, Colorado, 1989
• Keynote Speaker. "Advances in Diabetes Mellitus" at the Mexican Society of Nutrition and Endocrinology, Monterey, Mexico, 1989
• Keynote Speaker. "Obesity and Insulin Resistance" and "Meet the Professor: Diabetes Mellitus and Hypertension" at the IV International Congress of Medicine, Victoria, Mexico, 1989
• Invited Speaker. "Studies on the Mechanism of Insulin Resistance in Type II Diabetes." Merck, Sharp, & Dohme Co. Rahway, NJ, 1989
• Invited Speaker. "The Insulin Receptor and Post Receptor in Liver in NIDDM: Effects of Sulfonylureas." Fourth International Conference on Diabetes. University of Virginia, Charlottesville, VA, 1989
• Keynote Speaker. "Cellular Alterations in Liver, Muscle, and Adipose Tissues Responsible for Insulin Resistance in Diabetes." Meeting of the Diabetes Treatment Centers of American Foundation. 1989 Annual Physicians Conference. Palm Desert, CA, 1989
• Invited Speaker. "Diabetes is a Serious Disease" 42nd Annual Scientific Assembly of the North Carolina Academy of Family Physicians. Greensboro, NC, 1990
• Invited Speaker. "Cellular Alterations in Liver, Muscle, and Adipose Tissue Responsible for Insulin Resistance in NIDDM." Hershey Medical Center, Hershey, PA, 1990
• Invited Speaker. "Alterations in Insulin Receptors and Glucose Transporters in Obese and Diabetic Humans," at the Satellite Meeting of the XI Amsterdam International Congress of Pharmacology, "Pathophysiology and Treatment of Diabetes Mellitus" Montpellier, France, 1990
• Invited Speaker. "Altered Coupling of the Insulin Receptor with G i Protein in the Liver from Patients with NIDDM" at the International Symposium on Obesity and Diabetes Mellitus, Nagoya, Japan, 1990
• Invited Speaker. "Insulin Action in Adipose Tissue and Muscle in Human Obesity and Diabetes" at the 6th International Congress on Obesity, Kobe, Japan, 1990
• Invited Speaker, "Diagnosis and Treatment of Diabetes Mellitus" and "Insulin Resistance in Obesity and Diabetes Mellitus" at the LII National Medical Congress, San Jose, Costa Rica, 1990
• Invited Speaker, "Post-Receptor Defect in Type II Diabetes" American Diabetes Association, Minneapolis Affiliate, Minneapolis, MN, 1990
• Invited Speaker, "G-Proteins in Diabetes" at the Mayo Clinic, Rochester, NY, 1990
• Invited Speaker, "Overview of Alterations in Insulin Action in Human Diabetes" at the UCLA Symposium on Molecular and Cellular Biology, Park City, Utah, 1991
• Invited Speaker, "Mechanism of Insulin Resistance in NIDDM." Miles Laboratories, West Haven, Connecticut, 1991
• Invited Speaker, "Mechanisms and Management of Type II Diabetes." New Mexico Metabolism Symposium 1991. Taos, New Mexico, 1991
• Invited Speaker, "Mechanism of Insulin Resistance in Type II Diabetes. "Baylor College of Medicine, Houston, Texas, 1991
• Invited Speaker, "Diabetes Mellitus Prevention in the High Risk Patient," at the "Current Advances in Nutritional Medicine and Disease Prevention." Harvard Medical School, Boston, MA, 1991
• Invited Speaker, "NIDDM: Insulin Resistance vs. Insulin Secretion." NJ Affiliate of the ADA, Jamesburg, NJ, 1991
• Keynote Speaker, "Diabetes in the 90's." American Diabetes Association, NC Affiliate, Raleigh, NC, 1991
• Invited Speaker, "Insulin Resistance in NIDDM." University of Chicago, Chicago, IL, 1991
• Invited Speaker, "Carbohydrate Metabolism in Obesity and Diabetes." Nutrition and Diabetes Mellitus: Focus for the 1990's. A Satellite Symposium of the 14th IDF Congress. Baltimore, MD, 1991
• Invited Speaker, "Physiology of Insulin Action in Muscle." 14th International Diabetes Federation Congress, Washington, DC, 1991
• Invited Speaker, "Mechanism of Insulin Action." Satellite Symposium, 14th IDF Congress, Airily, VA, 1991
• Visiting Professor, "Cellular Alterations in Liver, Skeletal Muscle, and Adipose Tissue Responsible for Insulin Resistance in Obesity and Type II Diabetes." Symposium organized by the USSR Academy of Medical Sciences and the USSR Ministry of Health, Moscow, Russia, 1991
• Invited Speaker, "The IGF-1 Receptor in NIDDM: A Pathway to Bypass Insulin Resistance?" 39th Annual Clinical Society Scientific Meeting of the American Diabetes Association, New York Downstate Affiliate, New York City, 1991
• Invited Speaker, "Mechanism of Insulin Resistance in Obesity." Workshop sponsored by the National Diabetes Advisory Board, National Institutes of Health, Arlington, VA, 1991
• Invited Speaker, "Syndrome X." 11th Annual Day of Diabetes, American Diabetes Association, Columbus, Georgia, 1992
• Invited Speaker, "Insulin Resistance in Obesity and Non-Insulin Dependent Diabetes: Cause or Effect." Western Metabolism Club, Carmel, California, 1992
• Visiting Professor, "Fat 1992", Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 1992
• Invited Speaker, "Alteraciones a nivel de receptor y post receptor en la obesidad," XXV Congreso Nacional de la Sociedad Española de Ciencias Fisiológicas, Cordoba, Spain, 1992
• Keynote Speaker, "Aspectos moleculares de la diabetes mellitus no insulinodependiente", VIII Congreso Asociación Latinoamericana de Diabetes, Buenos Aires, Argentina, 1992
• Simposium Speaker, "Resistencia insulinica: su rol en diversos síndromes," VII Congreso Asociación Latinoamericana de Diabetes, Buenos Aires, Argentina, 1992
• Visiting Professor, "Weight Loss: Is it a Miracle?", Cooper Hospital/University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden, New Jersey, 1992
• Visiting Professor, "Insulin Resistance in Type II Diabetes", University of Pittsburgh, Pittsburgh, Pennsylvania, 1992
• Visiting Professor, "Pharmacological methods to bypass insulin resistance", Department of Biochemistry, University of Medicine and Dentistry of New Jersey/School of Osteopathic Medicine, Stratford, New Jersey, 1992
• Invited Speaker, "Insulin Resistance in Type II Diabetes", International Diabetes Federation Congress and the Dominican Republic Association of Endocrinology, Santo Domingo, Dominican Republic, 1993
• Visiting Professor, "Insulin Resistance", State University of New York Health Science Center at Brooklyn, Brooklyn, New York, 1993
• Visiting Professor, "Insulin Resistance: A target for the Clinical and Basic Investigator", The Milton S. Hershey Medical Center of the Pennsylvania State University, Hershey, Pennsylvania, 1993
• Invited Speaker, "Beyond the Basics: Neuropathy", the 13th Annual Diabetes Update '93 - American Diabetes Association, Philadelphia, Pennsylvania, 1993
• Invited Speaker, "Obesity: A Disease of the Adipose Tissue", National Institutes of Health, Bethesda, Maryland, 1993
• Invited Speaker, "The ABCs of Thyroid Disease", Eastern Shore Medical Symposium, Rehoboth Beach, Delaware, 1993
• Visiting Professor, "Gene Therapy for Insulin Resistance", Department of Biochemistry, School of Medicine, Universidad Complutense, Madrid, Spain, 1993
• Keynote Speaker, "Diabetes in Latinos" 8th Hispanic Medical Congress. The Interamerican College of Physicians and Surgeons, San Juan, Puerto Rico, 1993
• Invited Speaker, "The Translation of the DCCT to the Care of Patients with Type II Diabetes Mellitus" The Opening Symposium of the Joslin Center for Diabetes at Jefferson Medical College and Wills Eye Hospital, Philadelphia, 1994
• Invited Speaker, "Weight Loss in Severely Obese Subjects Prevents Type II Diabetes" International Symposium sponsored by the Chinese Nutrition Society and Shanghai Nutrition Society. Beijing, China, 1994
• Invited Speaker, "Thyroid Nodules" Diabetes-Endocrine Symposium, Medical College of Pennsylvania, Philadelphia, Pennsylvania, 1994
• Leadership Workshop: "Therapeutic Choices in NIDDM” 54th Annual Meeting, American Diabetes Association, New Orleans, 1994
• Invited Speaker, "Morbid Obesity and Diabetes" 7th International Congress of Obesity Satellite Symposium on Surgical Treatment of Obesity, Montreal, Quebec, Canada, 1994
• Keynote Speaker, "Insulin Resistance from the laboratory to the bedside", XVI Internal Medicine Chilean Congress, Santiago, Chile, 1994
• Symposium Speaker, "Current and future treatment of Diabetes Mellitus", XVI Internal Medicine Chilean Congress, Santiago, Chile, 1994
• Invited Speaker, "Prevention of diabetes: Is it possible? ", XVI Internal Medicine Chilean Congress, Santiago, Chile, 1994
• Invited Speaker, "Insulin Analogs" American Diabetes Association, Northern Illinois Affiliate’s Thirty-Seventh Annual Professional Symposium, Chicago, 1994
• Invited Speaker, "The Translation of the DCCT to the Care of the Patient with Type II Diabetes Mellitus", The Third Annual Controversies in Ambulatory Care Medicine, Philadelphia, 1994
• Visiting Professor, "Prevention of Type II Diabetes: The Challenge of the Next Decade", Medical Grand Rounds, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 1995
• Visiting Professor, “The Promotion of the Adipocyte: from storage to an endocrine cell”, Grand Rounds, University of Southern California School of Medicine, Los Angeles, CA, 1995
• Visiting Professor, “¿Es el adiosito inteligente?”, Consejo Superior de Investigaciones Científicas, Madrid, Spain, 1995
• Leadership Workshop: "Insulin Action Enhancers”, 55th Annual Meeting, American Diabetes Association, Atlanta, Georgia, 1995
• Invited Speaker, “Impact of weight loss by surgery on metabolic fitness”, FASEB Summer Conference on Genetic and Behavioral Influences on Nutrient Metabolism and Obesity, Copper Mountain, Colorado, 1995
• Visiting Professor, “Ob protein resistance in human obesity”, University of Chicago, Chicago, Illinois, 1995
• Plenary Speaker, “Studies of Leptin in Human Subjects”, NAASO Meeting, Baton Rouge, Louisiana, 1995
• Symposium Speaker, “The Gut and NIDDM”, Precose Specialist Investigator Meeting, Lincolnshire, IL, 1995
• Visiting Professor, “¿Terapia molecular de la diabetes o de la obesidad?”, V Congreso de Ciencias Farmacéuticas, Madrid, Spain, 1995
• Symposium Speaker, “Obesidad e insulino resistencia”, Sociedad Mexicana de Nutrición y Endocrinologia, Guanajuato, Mexico, 1995
• Symposium Speaker, “Leptin: The sensor of either fact mass or energy balance?”, American Society for Parenteral and Enteral Nutrition, Washington, DC, 1996
• Symposium Speaker, “Advances en Fisiopatologia de la Obesidad”, Canary Islands, Spain,1996
• Invited Speaker, “The Ob Gene in Human Obesity”, Western Metabolism Club, Carmel, CA, 1996
• Invited Speaker, “Ob Protein in Human Obesity”, IBC’s Second Annual International Symposium, Washington, DC, 1996
• Invited Speaker, “New Insights into the Pathophysiology and Therapy of Obesity: The Leptin Story”, Sixteenth Meeting of the International Scientific Committee on Diabetes, Cologne, Germany, 1996
• Invited Speaker, “Obesity: A Genetic Disease?”, Fourth Scientific Course in Pancreatic Islet Physiology and Pathology, Barcelona, Spain, 1996
• Invited Speaker, “Obesity: What Can be Done?”, Clinical Endocrinology, Harvard Medical School, Boston, MA, 1996
• Invited Speaker, "Human Obesity: What Have We Learned from Recent Genetic Insights?", Biomedicine '96, Washington, D.C., 1996
• Visiting Professor, "Leptin: The Tale of an Obesity Gene, Part II: Rx: Leptin Sc, qday and eat anything you want , East Carolina University, Greenville, NC, 1996
• Invited speaker, "Leptin Physiology and Pathophysiology in Man", American Society for Clinical Investigation, Washington, D.C., 1996
• Symposium Speaker, "Molecular therapy of obesity or diabetes? That is the question", XIII Meeting of the Spanish Diabetes Society, Oviedo, Spain, 1996
• Keynote speaker, "Leptin: The tale of an obesity gene: American Diabetes Association, Amelia Island, Florida, 1996
• Symposium Speaker: “Obesity and Diabetes” 4th Annual Congress on Women’s Health, Washington, D.C., 1996
• Invited Speaker, “Leptin: The Tale of an Obesity Gene” Annual Research Symposium, The Institute of Nutrition, University of North Carolina, Chapel Hill, NC, 1996
• Invited Speaker, “Ob Protein in Human Obesity” IBC’s Third International Symposium - Obesity - Advances in Understanding and Treatment. San Diego, CA, 1996
• Invited Speaker, “Meeting the Needs of patients: Emerging Options in Diabetes Care”. 34 th Annual Meeting of the European Association for the Study of Diabetes. Vienna, Austria, 1996
• Invited Speaker. “Obesity as a Metabolic Disease”. 6 th Annual Turamberry Conference. Aventura, Florida, 1996
• Invited Speaker. “The ob Gene Product and Nutrient Balance”. North American Association for the Study of Obesity. Breckenridge, Colorado, 1996
• Invited Speaker. XXVI Congreso de la Asociación Española de Pediatria. Valencia, Spain, 1996
• Invited Speaker. Human Obesity: Beyond Leptin Production. International Congress on Anti-Obesity Drug Targets. Cambridge, MA., 1996
• Invited Speaker. Insulina y leptina: La Extraña Pareja. VIII Congreso Sociedad Valenciana de Endocrinologia, Diabetes y nutrición. Valencia, Spain, 1996
• Invited Speaker. Chapter One in the Story of Leptin in Humans. American Society for Clinical Pharmacology and Therapeutics. San Diego, CA, 1997
• Invited Speaker. “Pathophysiology of Obesity”. Symposium of the German Endocrine Society. Lübeck, Germany, 1997.
• Invited Speaker. “Leptin: The Second Year”. 2 nd World Conference of the International Society for Molecular Nutrition and Therapy. Winnipeg, Canada, 1997.
• Invited Speaker. "Leptin: From Rodents to Humans". International Diabetes Federation Congress, Helsinki, Finland, 1997
• Invited Speaker. “Leptin: The New Lean Gene”. European Congress of Clinical Chemistry “Medlab97”, Basel, Switzerland, 1997
• Invited Speaker. Grand Rounds. "Leptin: From Rodents to Humans". Tulane University, New Orleans, Louisiana, 1997
• Invited Speaker, Plenary Session. "Current and Future Implications For the Use of Leptin in the Treatment of Obesity". NAASO Annual Meeting, Cancun, Mexico, 1997
• Invited Speaker, Conferencia “Diabetes, obesity y leptin”. Simposia Harvard - Joslin - SBD, XI Congreso Brasileño de Diabetes, Porto Alegre, Brazil 1997
• Medical Grand Rounds - “The Role of Leptin in Body Weight Regulation”. The University of Texas. San Antonio, TX, 1997
• Research Seminar: “Strategies for the treatment of type II diabetes”. Garvan Institute. Sydney, Australia, 1997
• Research Seminar: “Recent Advances on Leptin”. The Walter and Eliza Hall Institute for Medical Research. Melbourne, Australia, 1997
• Plenary Lecturer: “Strategies for the treatment of Obesity”. NAASO and American Society of Clinical Nutrition. Merida, Mexico, 1997
• Congreso Nacional de la Sociedad Española de Diabetes y Obesidad: “Leptina y obesidad". Caceres, Spain, 1997
• Invited Speaker - Bio-chemistry Seminar: “Strategy of drug discovery for the treatment of obesity”. Indiana University Medical Center. Indianapolis, IN, 1998
• Invited Speaker: American Diabetes Association “Leptin Pathway as a Target for Treatment”. San Francisco, California, 1998
• Invited Speaker: “Addressing the Accelerating Cost of Chronic Diseases: A Case Study”. Meeting the 21 st century healthcare challenge: A New Vision for Pharmaceutical Innovation. PHRMA, U.S. Embassy. Tokyo, Japan, 1998
• Opening Lecture of the XIV Sociedad Española de Diabetes: “En el camino a la cura de la Diabetes” Murcia, Spain, 1998
• Keynote lecture: “A new endocrine cell: Biology and Function of Adipocytes” 71 st Annual Meeting of the Japan Endocrine Society. Fukuoka, Japan, 1998
• Plenary lecture: “Leptin: the Past, Present and Future”. 71 st Annual Meeting of the Japan Endocrine Society. Fukuoka, Japan, 1998
• Plenary lecture: “From New Genes to New Treatments”. Satellite Symposium of the 8 th International Congress on Obesity. Paris, France, 1998
• Plenary lecture: “Emerging Therapies for Type II Diabetes”. 34 th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain, 1998
• Conferencia Magistral - Hospital Maciel: “ Leptina la Voz Del Adiosito”. Simposio Obesidad y Diabetes Mellitus - Cuando Y Como Intervenir. Montevideo, Uruguay, 1998
• Conferencia Magistral - Hospital Maciel: “Intervenciones Futuras en el Manejo de la Obesidad. Montevideo, Uruguay, 1998
• Lilly Symposium - Temas actuales en Diabetes. “Leptina y Obesidad”. Montevideo, Uruguay, 1998
• Invited Speaker: “Opciones terapéuticas en el síndrome de insulinorresistencia”. XI Congreso Argentino de Diabetes. Cordoba, Argentina, 1998
• Invited Speaker: “Leptina y Obesidad”. XI Congreso Argentino de Diabetes. Cordoba, Argentina, 1998
• Opening Lecture: “Leptina: La voz del Adiosito”. III Curso Sobre Investigaciones Biomedicas, Universidad de Granada y Consejo Superior de Investigaciones Científicas. Granada, Spain, 1998
• Symposium Speaker: “New Molecular Target for the treatment of Obesity”. “VI Meeting on Lipid Metabolism and Related Pathology” Instituto Superior de Ciencias da Sande-Sul. Costa da Caprica, Portugal, 1998
• Symposium Chairman and Speaker: “Neuroendocrine integration of appetite". Experimental Biology ‘99 Meeting. Washington, D.C. 1999
• Invited Speaker: "Leptin: The tale of an obesity gene and it's application to children". Building Bright Futures: Neonatal, Pediatric and Adolescent Nutrition in the 21 st Century. Indiana University School of Medicine, Indianapolis, IN. 1999
• Symposium Co-Chairman and Speaker. [lecture title omitted]. Genetics, Pathophysiology and Therapeutics on the Eve of a Major Conceptual Revolution. Euro-Conference Institute Pasteur. Paris, France, 1999
• Invited Speaker: "Insulin Resistance: A target for drug therapy at the CMES Ancillary Symposium, The Endocrine Society. Toronto, Canada, 2000
• Visiting Professor: “New targets for the treatment of obesity”. Medical Grand Rounds, University of Pittsburgh School of Medicine. Pittsburgh, PA. 2001
• Invited Speaker: “The treatment of diabetes in the new Millennium. Italian Society of Diabetes. Florence, Italy, 2002
• Symposium Speaker: “New Drug Therapies for Obesity” at Obesity: Molecular Causes
• and New Pathways for Treatment and Prevention. American Association for the Advancement of Science (AAAS) Annual Meeting. Denver, Colorado. 2003
• Keynote Speaker: “The Do’s and Do Not’s in Science: From Fuller Albright to the Present”. Graduate Student Research Day. East Carolina University. Greenville, NC. 2003
• Symposium Speaker: “Obesity and the Metabolic Syndrome: Identifying Underlying Mechanisms and Emerging Therapies for Pharmacological Treatment”. Pharmaceutical Education Associates. Washington, DC. 2003.
• Roundtable Participant: “Obesity and Cancer” National Dialogue on Cancer. Sponsored by President George W. and Barbara Bush. Kennebunkport, Maine. 2003
• Keynote Speaker and Chairperson: “Opportunities and Challenges of Therapeutic Development for Obesity”. World Obesity Congress & Expo. Washington, DC. 2004
• Symposium Speaker: “Addressing the Obesity Epidemic: From Bench to Bedside to Market”. The Endocrine Society’s 86 th Annual Meeting. New Orleans, LA. 2004
• Invited Speaker: “Overcoming Diabetes: A Long March from Discovery to Commercialization”. The Opening Ceremony of the Peking University Diabetes Center. Beijing, China. 2004
• Invited Speaker: “Anti-Obesity Drug Development: From Target Identification to Launch”. NAASO 2004 Scientific Meeting. Las Vegas, NV. 2004
• Invited Speaker: “New Therapies for Diabetes”. Leerink Swann/MEDACorp. Inaugural Health Care Conference. New York, NY. 2005
• Invited Speaker: “Insulin Sensitivity Enhancers for the Treatment and Prevention of Diabetes“ Diabetes and Obesity Research Day. East Carolina University, Brody School of Medicine. Greenville, NC. 2005
• Keynote Speaker and Chairperson: “New Opportunities and Challenges of Therapeutic Developments with Obesity and Weight Loss”. World Obesity Congress & Expo. Washington, DC. 2005
• Keynote Speaker: “On the Trail to ARREST the Progression of Type 2 Diabetes” College of Agriculture and Life Sciences, University of Arizona. Phoenix, AZ. 2005
• Keynote Speaker: “On the Trail to ARREST the Progression of the Metabolic Syndrome” 8 th Symposium Fundacion Lilly “New Approaches to the Metabolic Syndrome” San Lorenzo de El Escorial, Madrid. 2005
• Invited Speaker: “May be difficult at times…?” At The 5 th National Metabolic Day. Utrecht University, Amsterdam, The Nederland 2006
• Keynote Speaker: “Diabesity” 13 th Annual Kaiser Permanente Diabetes Symposium. Woodland Hills, CA 2007
• Invited Speaker and panel member: “Clinical Trials, Setting the stage for the future”. At the inaugural Clinical Trial Regional Exchange Group, The North Carolina Biotechnology Center. Greenville NC, 2007
• Post Graduate Course in Endocrinology: “Obesity”. At the Universidad Catolica, Montevideo, Uruguay, 2008
• Invited Speaker: “Peers for Progress”. At the School of Medicine, Maciel Hospital. Montevideo, Uruguay, 2008

Publications

Archive numbering retained. Entry 190 (a group-authored Diabetes Prevention Program paper) is withheld pending clarification of individual attribution. Bibliographic wording otherwise follows the archive.

1. Caro, J.F., A. Besarab, J.R. Burke, and J.A. Glennon. Propranolol: A possible role in the treatment of renal osteodystrophy. Lancet I I:451,1978.
2. Caro, J.F., and A. Besarab. Propranolol therapy for hyperparathyroidism. Lancet II:827,1978.
3. Caro, J.F., A.W. Meikle, J.H. Check, and S.N. Cohen. "Normal suppression" to dexamethasone in Cushing's disease: An expression of decreased metabolic clearance for dexamethasone. J. Clin. Endocrinol. Metab. 47:667,1978
4. Ballas, S.K., J.F. Caro, and O. Miguel. Quinidine-induced hemolytic anemia: Immunohematologic characterization. Transfusion 18:215,1978.
5. Besarab, A., and J.F. Caro. Mechanism of hypercalcemia in malignancy. Cancer 6:2276,1978.
6. Caro, J.F., A. Besarab, and J.A. Glennon. Symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for hypercalcemia in malignancy. Cancer Treat Reports 62:1561,1978.
7. Check, J.H., J.F. Caro, L. Jackson, K. Nowroozn and A.F. Rakoff. Clinical mixed gonadal dysgenesis without Y chromosome. Am. J. Obstet. Gynecol. 131:346,1978.
8. Check, J.H., J.F. Caro, and J.T. Flynn. Cystic gynecomastia in a male treated with clomiphene citrate. Infert. Sterility 30:713,1978.
9. Caro, J.F., A. Besarab, and J.T. Flynn. Prostaglandin E and hypercalcemia in breast carcinoma: Only a tumor marker? A need for prospective. Am. J. Med. 66:337,1979.
10. Caro, J.F., H.L. Israel, and J.A. Glennon. Galactorrhea in sarcoidosis: Dynamic studies of prolactin, growth and gonadotropic hormone levels. Am. J. Med. Sci. 277:1,1979.
11. Check, J.H., J.F. Caro, B. Kendall, L.A. Peris, and B.L. Wellenback. Cushing's syndrome in pregnancy: Effect of associated diabetes on fetal and neonatal complications. Am. J. Obstet. Gynecol. 44:846,1979.
12. Check, J.H., J.F. Caro, L. Criden, R. Meltz, and K. Brownstein. Leyding cell responsiveness with gonadal cell resistance to gonadotropin therapy in Kallman's syndrome. Am. J. Med. 67:495,1979.
13. Caro, J.F., J.H. Castro, and J.A. Glennon. Effect of long-term propranolol administration on parathyroid hormone and calcium concentration in primary hyperparathyroidism. Ann. Int. Med. 91:740,1979.
14. Caro, J.F., N.G. Sloane, and J.A. Glennon. Hyperthyroidism with normal serum T4, T3 and TBG immunoreactivity. J. Clin. Pat. 33:868,1980.
15. Caro, J.F., and P.D. Woolf. Pituitary-ovarian axis responsitivity to prolonged GnRH infusion in normal and hyperprolactinemic women. J. Clin. Endo. Metab. 50:999,1980.
16. Insogna, K.L., D.R. Bordley, J.F. Caro, and D.H. Lockwood. Osteomalacia and weakness due to excessive antacid ingestion. J.A.M.A. 244:2544,1980.
17. Castro, J.H., J.F. Caro, Kim, and J.A. Glennon. Effects of PTH infusion in primary hyperparathyroidism on plasma prolactin in man. J. Clin. Endo. Metab. 51:397,1980.
18. Caro, J.F., and J.M. Amatruda. Functional relationship between insulin binding, action and degradation. J. Biol. Chem. 255:10052,1980.
19. Caro, J.F., and J.M. Amatruda. Insulin receptors in hepatocytes: Post receptor events mediate down regulation. Science 210:1029,1980.
20. Caro, J.F., and J.M. Amatruda. The effects of fasting on glucagon binding and action in isolated hepatocytes. Metabolism 29:732,1980.
21. Caro, J.F. and J.A. Glennon, and H.L. Israel. Neuroendocrine studies in sarcoidosis. William, J.W. and Davis, B. H. (Eds.), Alpha Omega Publ. pp.587,1980.
22. Cech, J.N., R.B. Freeman, J.F. Caro, and J.M. Amatruda. Insulin action and binding in isolated hepatocytes from fasted, streptozotocin diabetic and older, spontaneously obese rats. Biochem. J. 188:839,1980.
23. Caro, J.F., and J.M. Amatruda. Evidence for the modulation of insulin action and degradation independently of insulin binding. Am. J. Physiol. 240:E325,1981.
24. Besarab, A., J.F. Caro, B.U. Ihle, J.F. Burke, and J.A. Glennon. Suppression of secondary hyperparathyroidism by propranolol in renal failure patient. Nephron 27:127,1981.
25. Besarab, A. and J.F. Caro. Increased absolute calcium binding to albumin in hypoalbuminaemia. J. Clin. Path. 34:1368,1981.
26. Basal, S., P.D. Woolf, J.A. Fischer, and J.F. Caro. Dopamine does not affect parathyroid function in man. J. Clin. Endo Metab. 54:651,1982.
27. Caro, J.F., and J.M. Amatruda. The regulation of lipid synthesis in freshly isolated hepatocytes and primary cultures of hepatocytes from fasted rats: The primary role of insulin. Metabolism 31:14,1982.
28. Caro, J.F., and J.M. Amatruda. Glucocorticoid-induced insulin resistance: The importance of post receptor events in the regulation of insulin binding and degradation. J. Clin. Invest. 69:866,1982.
29. Caro, J.F., G. Muller and J.A. Glennon. Insulin processing by the liver. J. Biol. Chem. 257:8459,1982.
30. Kauffman, J.M., and J.F. Caro. Insulin resistance in uremia: Characterization of insulin action binding and processing in isolated hepatocytes from chronic uremic rat. J. Clin. Invest. 71:698,1983.
31. Caro, J.F., and S. Jacoby. Lipid synthesis in freshly isolated and primary culture of rat hepatocytes from chronic uremic rats. J. Clin. Invest. 72:882,1983.
32. Caro, J.F., F. Folli, F. Cecchin, and M.K. Sinha. Chemical mediator of insulin action stimulates lipid synthesis and down regulates the insulin receptors in primary cultures of rat hepatocytes. Biochem. Biophys. Res. Commun. 115:375,1983.
33. Helineck, T.G., S. Sadel, and J.F. Caro. The effect of chronic uremia on glucagon binding and action in isolated rat hepatocytes. Metabolism 33:158,1984.
34. Caro, J.F., F. Cecchin, and M.K. Sinha. Is glycosylation in the liver needed for insulin binding, processing, and action: evidence for heterogeneity. J. Biol. Chem. 259:12810,1984.
35. Sinha, M.K., and J.F. Caro. Presence of an activator of pyruvate dehydrogenase in human circulation: elevation following a glucose load and possible relation to an insulin mediator. Biochem. Biophys. Res. Commun. 129:41,1985.
36. Chaplinski, T.J., T.E. Bennett, and J.F. Caro. Alteration in insulin receptor expression accompanying differentiation of HL-60 leukemia cells. Cancer Research 46:1203,1986.
37. Caro, J.F., O. Ittoop, W.J. Pories, D. Meelheim, E.G. Flickinger, F. Thomas, M. Jenquin, J.F. Silverman, P.G. Khazanie, and M.K. Sinha. Studies on the mechanism of insulin resistance in the liver from humans with non-insulin-dependent diabetes; insulin action and binding in isolated hepatocytes, insulin receptor structure and kinase activity. J. Clin. Invest. 78:249,1986.
38. Folli, F., M.K. Sinha, D. Brancaccio, and J.F. Caro. Insulin resistance in uremia: In vitro model in the rat liver using human serum to study mechanism(s). Metabolism 35:989,1986.
39. Dohm, G.L, J.F. Caro, and T. Fushiki. Mechanisms(s) responsible for increased glucose uptake during exercise. I.R.C.S. Med Sci 14:1174,1986.
40. Dohm, G.L., M.K. Sinha, J.F. Caro. Insulin receptor binding and protein kinase activity in muscles of trained rats. Am. J. Physiol. 252:E170,1987.
41. Caro, J.F. Non-Insulin-Dependent Diabetes Mellitus in Hispanic Americans, A Roundtable Discussion, Upjohn, Publication No. .
42. Sinha, M.K., W.J. Pories, E.G. Flickinger, D. Meelheim, and J.F. Caro. Insulin receptor kinase activity of adipose tissue from morbidly obese humans with or without noninsulin-dependent diabetes. Diabetes 36:620,1987.
43. Caro, J.F., W.J. Pories, E.G. Flickinger, D. Meelheim, O. Ittoop, M. Jenquin, M.K. Sinha, and G.L. Dohm. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin dependent diabetes. J. Clin. Invest. 79:1330,1987.
44. Forsayeth, J.R., J.F. Caro, M.K. Sinha, B.A. Maddux, and I.D. Goldfine. Monoclonal antibodies to the human insulin receptor that activate glucose transport but not insulin receptor kinase activity. Proc. Nat. Acad. Sci (USA) 84:3448,1987.
45. Caro, J.F., M.K. Sinha, and G.L. Dohm. Effect of chronic uremia on fructose 2,6-bisphosphate glycolytic and gluconeogenic enzymes in rat liver. Biochem. Biophys. Res. Commun. 144:352,1987.
46. Pories W.J., J.F. Caro, E.G. Flickinger, H.D. Meelheim, and M.S. Swanson. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Annals of Surgery 206:316,1987.
47. Sinha, M.K., L.G. Taylor, W.J. Pories, E.G. Flickinger, D. Meelheim, S. Atkinson, N.S. Sehgal, and J.F. Caro. Long-term effect of insulin on glucose transport and insulin binding in cultured adipocytes from normal and obese humans with and without non-insulin dependent diabetes. J. Clin. Invest 80:1073,1987.
48. Caro, J.F., J.A. Shafer, S.I. Taylor, S.M. Raju, N. Perrotti, and M.K. Sinha. Insulin stimulated protein phosphorylation in human plasma liver membranes: detection of endogenous or plasma membrane associated substrates. Biochem. Biophys. Res. Commun. 149:1008,1987.
49. Dohm, G.L., E.B. Tapscott, W.J. Pories, D.J. Dabbs, E.G. Flickinger, D. Meelheim, T. Fushiki, S.M. Atkinson, and J. F. Caro. An in vitro human muscle preparation suitable for metabolic studies. Decreased glucose transport in muscle from morbidly obese subjects. J. Clin. Invest. 82:486,1988.
50. Caro, J.F., J. Poulos, O. Ittoop, W.J. Pories, E.G. Flickinger and M.K. Sinha. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and regenerating and fetal rat liver. J. Clin. Invest. 81:976,1988.
51. Cecchin, F., O. Ittoop, M.K. Sinha and J. F. Caro. Insulin resistance in uremia: Insulin receptor kinase activity in liver and muscle from chronic uremic rats. Am. J. Physiol. 254:E394,1988.
52. Caro, J.F., F. Cecchin, F. Folli, C. Marchini, and M.K. Sinha. Effects of T3 on insulin action, insulin binding and insulin receptor kinase activity in primary cultures or rat hepatocytes. Horm. Metab. Res 20:327,1988.
53. Misbin, R.I., A. Green, I.M. Alverz, E.C. Almira, G.L. Dohm, and J.F. Caro. Inhibition of insulin stimulated glucose transport by a factor extracted from the serum of a patient with insulin resistance. Diabetes 37:1217,1988.
54. Caro, J.F., S.M. Raju, M.K. Sinha, I.D. Goldfine, and G.L. Dohm. Heterogeneity of 5human liver, muscle, and adipose tissue insulin receptor. Biochem. Biophys. Res. Commun. 151:123,1988.
55. Goldfine, I.D. and J.F. Caro. Molecular and Cellular Biology of the Insulin Receptor in Diabetes Mellitus. In: Molecular and Cellular Biology of Diabetes Mellitus, Vol II. B Draznin, S. Melmed and D. LeRoith, (Eds.) Alan R. Liss, Inc., New York, pp.11,1989.
56. Silverman, JF., W. J. Pories, J.F. Caro. Liver Pathology in Diabetes Mellitus and Morbid Obesity: Clinical, Pathologic, and Biochemical Considerations. S. Sommers, P.P. Rosen, and R.E. Fechner (Eds). Appleton & Lange. Pathology Annual 24:275,1989.
57. Caro, JF., G.L.Dohm, W.J. Pories, and M.K. Sinha. Cellular Alterations in Liver, Skeletal, Muscle, and Adipose Tissue Responsible for Insulin Resistance in Obesity and Type II Diabetes. Diabetes Metabolism Review 5:665,1989.
58. Contreras, N.I. and J.F. Caro. The Collisional Hypothesis of Insulin Action, Receptor Internalization and Diabetes. TIBS 14:399,1989.
59. Thakkar, J.K., R. DiMarchi, K. MacDonald and J.F. Caro. Effect of insulin and insulin-like growth factors I and II on phosphatidylinositol and phosphatidylinositol-4.5-biophosphate breakdown in liver plasma membranes from humans with and without type II diabetes. J. Biol. Chem. 264:7169,1989.
60. Caro, J.F., O. Ittoop, and M.K. Sinha. Glyburide but not ciglitazone enhances insulin action in the liver independent of insulin receptor kinase activation. Metabolism 38:606,1989.
61. Sinha, M.K., C. Buchanan, N. Leggett, L. Martin, P.G. Khazanie, R. DiMarchi, W.J. Pories, and J.F. Caro. Mechanism of IGF-I stimulated glucose transport in human adipocytes: demonstration of specific IGF-I receptors not involved in stimulation of glucose transport. Diabetes 38:1217,1989.
62. Caro, J.F., G.L. Dohm, and M.K. Sinha. Insulin Resistance in Obesity. Adv. Diabetologia 2:1,1989.
63. Moller, D.E., A. Yokota, J.F. Caro, and J.S. Flier. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Molecular Endocrinology 3:1263,1989.
64. Caro, J.F., M.K. Sinha, and G.L.Dohm. Insulin Resistance in Obesity. In: Obesity Towards a Molecular Approach. Alan R. Liss, Inc., New York. Vol. 132:203,1990.
65. Marcuard, S.P., B. Dunham, A. Hobbs, and J.F. Caro. Availability of insulin from total parenteral nutrition (TPN) solutions. J. Parent Enter Nutri. 14:262,1990.
66. Caro, J.F. "Mechanisms de accion de la insulina y resistencia a la insulina en la obsidad y diabetes tipo 2." In: Los islotes de Langerhans: un organo multiendocrino. (Enrique Blazquez y Jorge Tamarit, eds.), Fundacion Romon Areces, pp.203,1990.
67. Thakkar, J.K., M.S. Raju, and J.F. Caro. 3H Myoinositol incorporation into phospholipids in liver microsomes from humans with and without Type II diabetes: The lack of synthesis of glycosyl-phosphatidyl inositol, precursor of the insulin mediator inositol phosphate glycan. J. Biol Chem. 265,10:5475,1990.
68. Dohm, G.L., W. Elton, S.M. Raju, N. Mooney, R. DiMarchi, W.J. Pories, E.G. Flickinger, S.M. Atkinson, and J.F. Caro. IGF-I stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 39:1028,1990.
69. Contreras, I., G.L. Dohm, S. Abdallah, A. Wells, N. Mooney, A. Rovira, and J.F. Caro. The effect of fasting on in vivo activation of the insulin receptor tyrosine kinase. Biochem. J. 265:887,1990.
70. Burguera, B., H. Werner, M. Sklar, Z Shen-Orr, B. Stannard, C.T. Roberts, Jr., S.P. Nissley, S.J. Vore, J.F. Caro, and D. LeRoith. Liver regeneration is associated with increased expression of the insulin-like growth factor II/mannose-6-phosphate receptor. Molecular Endocrinology 4:1539,1990.
71. Sinha, M.K. and J.F. Caro. Effect of insulin and tunicamycin on insulin receptor kinase activity in primary cultures of rat hepatocytes. Endocrinologia 37:18,1990.
72. Silverman, J.F., K. O'Brien, S. Long, N. Leggett-Frazier, P.G. Khazanie, W.J. Pories, H.T. Norris, and J.F. Caro. Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenter. 85:1349,1990.
73. Sinha, M.K., C. Buchanan, C. Raineri-Maldonado, P. Khazanie, S. Atkinson, R. DiMarchi, and J.F. Caro. IGF-II receptors and IGF-II stimulated glucose transport in human fat cells. Am. J. Phys. 258:E534,1990.
74. Poulus, J.F., E.L. Treadwell, K. O'Brien, S. Long, and J.F. Caro. The presence of autoantibodies to the IGF-I, IGF-II and insulin receptor in patients with Type II (noninsulin-dependent) diabetes, impaired glucose tolerance and autoimmune diseases. Adv. Diabetologia 3:83,1990.
75. Caro, J.F. Effects of glyburide on carbohydrate metabolism and insulin action in the liver. Am J. Med. 89:17,1990.
76. Chen, J.J., H.Y. Lee, and J.F. Caro.Contribution of non-insulin-dependent diabetes mellitus to the insulin metabolic clearance rate of morbidly obese patients. Clin. Med. J. (Taipei) 45:285,1990.
77. Burguera, B. and J.F. Caro. Mechanism of action of insulin: first chapter. Endocrinologia 37:1,1990.
78. Barakat, H.A., V.D. McLendon, J.W. Carpenter, R.H.L. Marks, N. Leggett, K. O'Brien, and J.F. Caro. Lipogenic potential of liver from morbidly obese patients with and without noninsulin-dependent diabetes. Metabolism 40:280,1991.
79. Chen J.J., N. Leggett, K.O'Brien, S. Long, P.G. Khazanie, G.L. Dohm, M.K. Sinha, H.A. Barakat, W.J. Pories and J.F. Caro. "Insulin action in obesity and diabetes." In: Progress in Obesity Research. John Libbey and Company Ltd.,London, England, Chapter 57, pp.365,1991.
80. Caro, J.F., S.R. Madhu, J.C. Hale, N. Leggett-Frazier, S. Long, W.J. Pories. Altered coupling of the insulin receptor with G1 protein in the liver from patients with NIDDM. New Directions in Research and Clinical Works for Obesity and Diabetes Mellitus In: Excerpta Medica International Congress Series, Elsevier Science Publishers, pp.53,1991.
81. Sinha, M.K., C. Raineri-Maldonado, C. Buchanan, W.J. Pories, C.C. Su, P.F. Pilch, and J.F. Caro. Adipose tissue glucose transporters in non-insulin-dependent diabetes mellitus: decreased levels of muscle/fat and erythroid isoforms. Diabetes 40:472,1991.
82. Caro, J.F., J. Hodges, and M.K. Sinha. Increased insulin responsiveness in hepatocytes incubated with free fatty acid-poor albumin. Horm. Metab. Res. 23:362,1991.
83. Friedman, J.E., R.W. Dudek, D.S. Whitehead, D.L. Downes, W.R. Frisell, J.F. Caro, and G.L. Dohm. Immunolocalization of glucose transporter Glut4 with human skeletal muscle. Diabetes 40:150,1991.
84. Dohm, G.L., C.W. Elton, J.E. Friedman, P.F. Pilch, W.J. Pories, S.M. Atkinson, Jr., and J.F. Caro. Decreased expression of glucose transporter in muscle from insulin resistant patients. Am. J. Physiol. 260:E459,1991.
85. Friedman, J.E., G.L. Dohm, C.W. Elton, A. Rovira, J.J. Chen, N.L. Frazier, S.M. Atkinson Jr., S.D. Long, and J.F. Caro. Muscle insulin resistance in uremic humans: Glucose transport, glucose transporters, and insulin receptors. Am. J. Physiol. 261:E87,1991.
86. Caro, J.F. Insulin resistance in obese and non-obese man. J. Clin. Endo Metab. 73:691,1991.
87. Burguera, B. and Caro, J.F. Alterations in insulin receptors and glucose transporters in obesity and Type 2 diabetes. In: Frontiers in Diabetes Research. Lessons from Animal Diabetes III. Eleazar Shafrir (Ed.), Smith-Gordon and Company, Ltd. pg. 269,1991.
88. Burguera B., Long S., Frank H.B., DiMarchi R., Caro, J.F. Binding of insulin-like growth factors, proinsulin and proinsulin analogs to human liver, muscle and adipose tissue receptors. J. Clin. Endocrinol. Metab. 72:1238,1991.
89. Burguera B, Madigan T., Mustafa, S.J., Frank, H.B., DiMarchi, R. and Caro J.F. The interaction of proinsulin with insulin-like growth factors I and II receptors in smooth muscle membranes from bovine coronary arteria. Av Diabetol 5:187,1992.
90. Freidman, J.E., G.L. Dohm, N. Leggett-Frazier, C.W. Elton, E.B. Tapscott, W.P. Pories, and J.F. Caro. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss: Effect on muscle glucose transport and glucose transporter GLUT-4. J. Clin. Invest. 89:701,1992.
91. Burguera, B., H. Werner, M.Couce, D. LeRoith, J.F. Caro. Regulation of IGF's receptor. Regulation of growth hormone and somatic growth. LF de la Cruz (Ed.) Elsevier Amsterdam. pp.271,1992.
92. Caro, J.F. Mecanismos de la Accion de la insulina y resistencia a la insulina en la obesidad y diabetes tipo II. J Latino Amer. Soc. Diab. 14:10,1992.
93. Pories, W.J., K.G. MacDonald, E.J. Morgan, M.K. Sinha, G.L. Dohm, M.S. Swanson, H.A. Barakat, P.G. Khazanie, N. Leggett-Frazier, S. D. Long, K.F. O'Brien, and J.F. Caro. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am. J. Clin. Nutr. 55:582S,1992.
94. Caro, J.F., M. Jenquin, S. Long. Effects of phorbol esters on insulin receptor function and insulin action in hepatocytes: evidence for heterogeneity. Mol. Cell Biochem. 109:115,1992.
95. Contreras, I., J.F. Caro, L. Aveledo, K. Diaz, P. Durrego, and J.R. Weisinger. In Chronic uremia, insulin activates receptor kinase but not pyruvate dehydrogenase. Nephron. 61:71,1992.
96. Pories, W.J., K.G. MacDonald, E.G. Flickinger, G.L. Dohm, M.K. Sinha, H.A. Barakat, H.J. May, P. Khazanie, M.S. Swanson, E. Morgan, N. Leggett-Frazier, S.D. Long, B.M. Brown, K. O'Brien, and J.F. Caro. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann. Surg. 251:633,1992.
97. Usala, A.L., Madigan, T., Burguera, B., Sinha, M.L., Caro, J.F., Powell, J.G., and Butler, P.C. Brief Report: Treatment of insulin resistance diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. New England Journal of Medicine. 327:853,1992.
98. Caro, J.F. Diabetes and Hypertension: Not the Final Chapter. Diabetes Care. 16:540,1992.
99. Barakat, H.A., N. Mooney, K. O'Brien, S. Long, P. Khazanie, W.J. Pories, and J.F. Caro. Coronary artery disease risk factor in morbidly obese women with normal glucose tolerance. Diabetes Care. 16:144,1992.
100. Considine, R.V. and Caro, J.F. Protein Kinase C: Mediator or Inhibitor of Insulin Action? J Cell Biochem. 52:1,1992.
101. Serrano, J., C.M. Mateo and J.F. Caro. Insulin resistance: Cellular and molecular mechanisms. In: Recent Advances in Endocrinolgoy and Metabolism. Vol. 4. C.R.W. Edwards and D.W. Lincoln (Eds.), Churchill Livingstone, London, UK. Chapter 11.pp.167,1992.
102. Burguera, B., Couce, M.E., Caro, J.F. Fisiologia del receptor insulin-like growth factor-II/manosa 6 fosfato (IGF-II/Man 6-P R). In: Advances en Endocrinologia Celular Y Molecular. F.F. Casanueva, C. Dieguez, (Eds.), Fundacion Ramon Areces. pp.221,1992.
103. Burguera, B., H. Werner, M. Couce, C.T. Roberts, D. LeRoith, J.F. Caro. Physiology of the Insulin-Like Growth Factor I and Insulin-Like Growth Factor II/Mannose 6-Phosphate Receptors. LF de la Cruz (Ed.) Elsevier Amsterdam. pp.271,1992.
104. Burguera, B., Parzianella, N.A., Caro, J.F. Estudio de la expresion del transportador de glucosa GLUT-2 en el higado de pacientes diabéticos. In Fronteras Endocrinologia. C. Dieguez, F.F. Casanueva (Eds.) Diaz Santos, Madrid, pp.19,1992.
105. Sinha, M.K., C. Buchanan, C. Raineri-Maldonado, I.D. Goldfine and J.F.Caro. Regulation of glucose transport by insulin and monoclonal insulin receptor antibodies in adipocytes of patients with NIDDM. Adv Diabetologia 5:90,1992.
106. Ravindra, R, J.F. Caro. Insulin stimulates GDP release from G proteins in the rat and human liver plasma. J Cell Biochem 53:181,1993.
107. Arky, R.A., Caro, J.F., Johnson, C., Knowler, W.C., McManus, K., Moore, M.A., Sheps, S.G., Simonson, D.C. and Spratt, I. Consensus Development Conference on the Treatment of Hypertension in Diabetes. Diabetes Care. 16:1394,1993.
108. Kolaczynski, J.W. and Caro, J.F. Insulin-like Growth Factor-1 Therapy in Diabetes: Physiological Basis, Clinical Benefits and Risks. Ann Int Med 129:47,1994.
109. Kolaczynski, J.W. and Caro, J.F. Insulin-like Growth Factor-1 Therapy for Diabetes Mellitus? Diabetes Care. 17:92,1994.
110. Caro, J.F. Insulin-Dependent Diabetes Mellitus in Adults. In: Current Therapy in Endocrinology and Metabolism, 5th Edition. Bardin (Ed.) Mosby-Year Book, Inc. pp.384,1994.
111. Burguera, B., Dudek, R.W., Caro, M., Slieker, L.J., Heath, W.F., Busby, J. and Caro J.F. Upregulation of GLUT-2 protein levels in rat liver by chronic glucose administration. Adv Diabetologia 7:23,1994.
112. Kolaczynski, J.W., Morales, L.M., Moore, J.H., Considine, R.V., Pietrzkowski, Z., Noto, P.F. and Caro. J.F. A new technique for biopsy of human abdominal fat under local anesthesia with lidocaine. Acute and long term effects of lidocaine on human adipocytes in vitro revised. Int. J. Obesity 18:161,1994.
113. Caro, J.F., M.S. Raju, M. Caro, C.J. Lynch, J.H. Exton, J.K. Thakkar, L. Roy, J.C. Hale, and W.J. Pories. Guanine nucleotide binding regulatory proteins in liver from humans with type II diabetes: evidence for altered "cross-talk" between the insulin receptor and Gi-proteins. J Cell Biochem 54:309,1994.
114. Long, S.D., O'Brien, K, McDonald, K.G., Frazier, N.L., Swanson, M.S., Pories, W.J., Caro, J.F. Weight loss prevents the progression of impaired glucose tolerance to type II diabetes: A longitudinal interventional study. Diabetes Care 17:372,1994.
115. Poulos, J.E., N. Leggett-Frazier, P. Khazanie, S. Long, R. Sportsman, K. MacDonald, and J.F. Caro. Circulating insulin-like growth factor concentrations in morbidly obese patients with NIDDM in response to the gastric bypass procedure. Horm. Met. Res. 26: 478,1994.
116. Friedman, J.E., J.F. Caro, W.J. Pories, J.L. Azevedo, and G.L. Dohm. Glucose Metabolism in Incubated Human Muscle: effect of obesity and non-insulin dependent diabetes mellitus. Metabolism 8: 1042,1994.
117. Burguera, B., C.W. Elton, J.F. Caro, E.B. Tapscott, W.J. Pories, R. DiMarchi, K. Sakano and G.L. Dohm. Stimulation of glucose uptake by insulin-like growth factor II in human muscle is not mediated by the insulin-like growth factor II/mannose 6-phosphate receptor. Biochem J 300:781,1994.
118. Caro, J.F. and Rastogi, R.: Diabetes. In: Talking Health with Dr. Brian McDonough. B.P. McDonough (Ed.), Temple University Press, Philadelphia. Chapter 5, pp.71,1994.
119. Kennedy, J. and J.F. Caro. Sex hormones and singers: endocrine effects on voice. J National Assoc Teachers of Singing. November/December,1994.
120. Caro, J.F., S. Triester, V.K. Patel, E.B. Tapscott, N.L.Frazier and G. L. Dohm. Liver glucokinase: Decreased activity in patients with type II diabetes. Horm Met Res. 27:18,1995.
121. Poulos, J.E., T. Madigan, J. Serrano, J. Busby and J.F. Caro. The effects of GTPγS on insulin binding to human liver plasma membranes. Horm Met Res. 27:253,1995.
122. Considine, R.V., M.R. Nyce, L.E. Allen, L.M. Morales, S. Triester, J. Colberg, S.L. Jacoby and J.F. Caro. Protein Kinase C is Increased in the Liver of Humans and Rats with Non-Insulin-Dependent Diabetes Mellitus: An Alteration not due to Hyperglycemia. J Clin Invest. 95:2938,1995.
123. Considine, R.V., E.L. Considine, C.J. Williams, M.R. Nyce, S.A. Magosin, T.L. Bauer, E.L. Rosato, J. Colberg and J.F. Caro. Evidence Against Either a Premature Stop Codon or the Absence of Ob Gene mRNA in Human Obesity. J Clin Invest. 95:2986,1995.
124. Burguera, B., R.D. Dudek, and J.F. Caro. Liver GLUT-2 protein is not Upregulated in Non-Insulin Dependent Diabetes. Horm. Met. Res. 27:341,1995.
125. Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson and B.M. Spiegelman. Increased adipose tissue expression on TNF-α in human obesity and insulin resistance. J. Clin. Invest. 95: 2409,1995.
126. Moore, J.H., J.W. Kolaczynski, L.M. Morales, R.V. Considine, Z. Pietrzkowski., P.F. Noto and J.F. Caro. Viability of Fat Obtained by Syringe Suction Lipectomy: Effects of Local Anesthesia with Lidocaine. Aesth Plast Surg. 19:335,1995.
127. Caro, J.F. Weight loss in severely obese subjects prevents type II diabetes and reveres insulin resistance and early type II diabetes. Asia Pac. J. of Clin. Nut. 4:326,1995.
128. Caro, J.F. Biochemical Defects of Insulin Action in Humans. In: Diabetes Mellitus: A Fundamental and Clinical Text.. Chapter 57. Mosby-Year Book, Inc.,1995.
129. Fair-Covely, R.M., and J.F. Caro. Diabetes Mellitus. In: Current Diagnosis, 9th Ed.,1995.
130. Sinha, M.K., J.P. Ohannesian, M.L. Heiman, A. Kriaciunas, T.W. Stephens and J.F. Caro. Nocturnal rise of leptin in lean, obese and non-insulin dependent diabetes mellitus subjects. J. Clin. Invest. 97:1344,1995.
131. Considine, R.V., M.K. Sinha, M.L. Heiman, A. Kriaciunas, T.W. Stephens, M.R. Nyce, J.P. Ohannesian, C.C. Marco, L.J. McKee,. T.L. Bauer and J.F. Caro. Serum Immunoreactive-Leptin concentrations in normal weight and obese humans. New Engl J Med. 334:292,1996.
132. Considine, R.V., M.R. Nyce, L.M. Morales, S.A. Magosin, M. Sinha, T.L. Bauer, E.L. Rosato, J. Colberg, and J.F. Caro. Paracrine Stimulation of Preadipocyte Enriched Cultures Proliferation by Mature Adipocytes. Am J Physiol. 270:E895,1996.
133. Laine, C., and J.F. Caro. Preventing Complications in Diabetes Mellitus: The Role of the Primary Care Physician. Medical Clinics of North America. 80:457,1996.
134. Kennedy, J.W., and J.F. Caro. The ABC’s of Hyperthyroidism in the older patient. Geriatrics. 51:22,1996.
135. Kolaczynski, J., and J.F. Caro. Molecular Mechanism of Insulin Resistance in Human Obesity. Curr Opin. in Endocrinol. and Diabetes. 3:36,1996.
136. Lynn, R.B., G.Y Cao, R.V. Considine, T.M. Hyde and J.F. Caro. Autoradiographic localization of leptin binding in the choroid plexus of ob/ob and db/db mice. Biochem. Biophys. Res. Comm. 219:884,1996.
137. Hassink, S.G., E. DeLancey, D.V. Sheslow, J.F. Caro, R.V. Considine, J.W. Kolaczynski and A. Spitzer. Serum leptin levels correlate with all indirect measure of adiposity in obese children. Pediatrics. 98:201,1996.
138. Kolaczynski, J.W., M.R. Nyce, R.V. Considine, G. Boden, J.J. Nolan, R. Henry, S.R. Mudaliar, J. Olefsky and JF. Caro. Acute and Chronic Effect of Insulin on Leptin Production in Humans: Studies in vivo and in vitro. Diabetes. 45:699,1996.
139. Considine, R.V., E.L. Considine, C.J. Williams, M.R. Nyce, P.L. Zhang, I. Opentanova, J.P. Ohannesian, J.W. Kolaczynski, T.L. Bauer, J.H. Moore and J.F. Caro. Mutation screening and identification of a sequence variation in the human Ob gene coding. Biochem. Biophys. Res. Comm. 220:735,1996.
140. Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson and B.M. Spiegelman. Differential regulation of adipose tissue TNF receptors in human obesity and insulin resistance. 140.Diabetes. 46:451,1996.
141. Kolaczynski, J.W., R.V. Considine, J. Ohannesian, C. Marco, I. Opentanova, M.R. Nyce, M. Myint and J.F. Caro. Responses of leptin to short-term fasting and refeeding in humans: A link with ketogenesis but not ketones themselves. Diabetes 45:1511,1996.
142. Considine, R.V., E.L. Considine, C.J. Williams, T.M. Hyde and J.F. Caro. The Hypothalamic Leptin Receptor in Humans: Identification of Incidental Sequence Polymorphisms and Absence of the db/db Mouse and fa/fa Rat Mutations. Diabetes 19:992,1996.
143. Laine, C. and J.F. Caro. 1996. Subdiagnostico y deficiencia en el tratamiento de diabetes tipo 2. MEDICO Interamericano 15:196,1996.
144. Sinha, M.K., I. Opentanova, J. P. Ohannesian, M.L. Heiman, J. Hale, G.W. Becker, R.R. Bowsher, T.W. Stephens and J.F. Caro. Evidence of Free and Bound Leptin in Human Circulation: Physiological significance in lean and obese subjects and during short-term fasting. J. Clin. Invest. 98:1277,1996.
145. Nolan, J., J. Olefsky, M.R. Nyce, R.V. Considine and J.F. Caro. Effect of Troglitazone on Leptin Production: Studies in vitro and in human subjects. Diabetes. 45:1276,1996.
146. Hickey, M., R.V. Considine, R. Israel, M. McCammon, G. Tyndall, T. Mahar, J. Houmard and J.F. Caro. Leptin is related to body fat content in male distance runners. Am. J. Physiol. 271:E938,1996.
147. Caro, J.F., J.W. Kolaczynski, M.R. Nyce, J.P. Ohannesian, I. Opentanova, W.H. Goldman, R.B. Lynn, P.L. Zhang, M.K. Sinha, and R.V. Considine. Decreased CSF/Serum leptin ratio in human obesity: A possible mechanism for "apparent" leptin resistance. Lancet. 348:159,1996.
148. Caro, J.F., M.K. Sinha, J.W. Kolaczynski, P.L. Zhang, and R.V. Considine. Leptin: The Tale of an obesity gene. Diabetes 45:1455,1996
149. Sinha, M.K., J. Sturis, J. Ohannesian, S. Magosin, T. Stephens, M.L. Heiman, K.S. Polonsky, and J.F. Caro. Ultradian Oscillations of Leptin Secretion in Humans. Biochem. Biophy. Res. Commun. 228:733,1996.
150. Hickey, M. S., R. G. Israel, S. N. Gardiner, R. V. Considine, M. R. McCammon, G. L. Tyndall, J. A. Houmard, R. H. L. Marks, and J. F. Caro. Gender Differences in Serum Leptin Levels in Humans. Biochem. Mol. Med. 59:1,1996.
151. Kolaczynski, J. W., and J. F. Caro. Tolerance in Individuals with Diabetes. Chapter 10. The Clinical Evaluation of a Food Additive, CRC Press,1996.
152. Kolaczynski, J.W., J. P. Ohannesian, R. V. Considine, C. C. Marco, and J. F. Caro. Response of Leptin to Short-Term and Prolonged Overfeeding in Humans. J. Clin. Endo. Metab. 81:4162,1996.
153. Kennedy, J. W. and J. F. Caro. The ABCs of Managing Hyperthyroidism in the Older Patient. Geriatrics. 51:22,1996.
154. Wing, R. R., M. K. Sinha, R. V. Considine, W. Lang and J. F. Caro. Relationship between Weight Loss Maintenance and Changes in Serum Leptin Levels. Horm. Metab. Res. 28:698,1996.
155. Considine, R. V., and J. F. Caro. Leptin: Genes, Concepts and Clinical Perspective. Horm. Metab. Res. 46:249,1997.
156. Considine, R. V., M. R. Nyce, J. W. Kolaczynski, P. Zhang, J. P. Ohannesian, J. H. Moore, Jr., J. W. Fox, and J. F. Caro. Dexamethasone stimulates leptin release from human adipocytes: Unexpected inhibition by insulin. J. Cell. Biochem. 65:254,1997.
157. Hickey, M. S, J. A. Houmard, R. V. Considine, G. L. Tyndall, J. B. Midgette, K. E. Gavigan, L. Weidner, M. R. McCammon, R. G. Israel, and J. F. Caro. Gender-dependent effects of exercise training on serum leptin levels in humans. Am. Physiol. Soc. E562,1997.
158. Caro, J.F. Leptin is Normal in PCOS, an Editorial about 3 “Negative” Papers. J. Clin. Endo. & Metab. 82:1685,1997..
159. Casanueva, F.F., C. Dieguez, V. Popovic, R. Peino, R. Considine, and J.F. Caro. Serum immunoreactive-leptin concentrations in patients with anorexia nervosa before and after partial weight recovery. 1997. Biochem. and Mol. Med. 60:116,1997.
160. Sreenan, Seamus, J. F. Caro, and S. Refetoff. Thyroid Dysfunction is not Associated with Alterations in Serum Leptin Levels. Thyroid. 7:407,1997.
161. Considine, R. V. and .J. F. Caro. Leptin and the Regulation of Body Weight. Int. J. Biochem. Cell Biol. 29:1255,1997.
162. Hickey, M.S., J. A. Houmard, R. V. Considine, G. L. Tyndall, J. B. Midyette, K. E. Gavigan, M. L., Weidner, M. R. McCammon, R. G. Israel, and J. F. Caro. Exercise training improves insulin action but does not change serum leptin levels in obese humans. Amer. J. Physiol. 59:1,1997.
163. Sharma, K., R. Considine, B. Michael, S. Dunn, L. Weisberg, B. Kurnik, P. Kurnik, J. O’Connor, M. Sinha and J. F. Caro. Plasma Leptin is Cleared by the Kidney and is Markedly Elevated in emodialysis Patients. Kidney Int. 51:1980,1997.
164. Caro, J. F., Sinha, M. K., Kolaczynski, J. W., Zhang, P., Considine, R. V. Leptin: The tale of an obesity gene. Leptin as alternative treatment for human obesity. BioMedicina,1997..
165. Vidal-Puig, Antonio J., R. V. Considine, Mercedes Jimenez-Linan, Ariel Werman, Walter J. Pories, Jose F. Caro, and Jeffrey Flier. Peroxisome Proliferator - activated receptor Gene Expression in Human Tissues Effects of Obesity, Weight Loss, and Regulation by Insulin and Glucocorticoids. J. Clin. Invest. 99:2416,1997.
166. Schoeller, D. A., Cella, L. K., Sinha, M. K. , and Caro, J. F. Entrainment of the Diurnal Rhythm of Plasma Leptin to Meal Timing. J. Clin. Invest. 100:1882,1997.
167. Wadden, T. A., R. V. Considine, G. D. Foster, D. A. Anderson, D. B. Sarwer, and J. F. Caro. Short- and Long-Term Changes in Serum Leptin in Dieting Obese Women: Effects of Caloric Restriction and Weight Loss. J. Clin. Endo. & Meta. 83:214,1998.
168. Sinha, M. K. and J. F. Caro. Clinical Aspects of Leptin. Vitam. Horm. 54:1,1998
169. Martin, L.J., .P.J.H. Jones, R.V. Considine, W. Su, N.F. Boyd and J.F. Caro. Serum Leptin Levels and Energy Expenditure in Normal Weight Women. Can. J. Physiol. Pharmacol. 76:237,1998.
170. Stephens, T. W. and Caro, J. F. To be Lean or not to be Lean, Is Leptin the Answer? Exp. Clin. Endocrinol. 106:1,1998.
171. Caro, J.F. Leptin: From 1958 to the Present. Can. J. Diab. Care. 22:518,1998
172. Hickey, Matthew S., Pories, Walter J., Macdonald, Kenneth G., Cory, Kelly A., Dohm, G. Lynis, Swanson, Melvin S., Israel, Richard G., Considine, Robert V., Caro, Jose F., Houmard, Joseph A. A New Paradigm for Type 2 Diabetes Mellitus: Could it be a Disease of the Forgut? Ann. Surg. 227:637,1998.
173. Heini, AF, Lara-Castro, C, Kirk, KA, Considine, RV, Caro, JF, and RL Weinsier. Association of leptin and hunger-satiety ratings in obese women. Int. J. Obes. Relat. Metab. Disord. 22:1084,1998.
174. Heiman, M. L., Chen, Yanyun, and Caro, J.F. Leptin participates in the regulation of glucocorticoid and growth hormone axes. J. Nutr. Biochem. 9:553,1998.
175. Lage, M., R. V. Garcia-Mayor, M. A. Tome, F. Cordido, F. Valle-Inclan, R. V. Considine, J. F. Caro, C. Dieguez, F. F. Casanueva. Serum leptin levels in women throughout pregnancy and the postpartum period and in women suffering spontaneous abortion. Clin.Endocrinol. 50:211,1999.
176. Considine, R. V. and J. F. Caro. Pleiotropic cellular effects of leptin. Curr Opin in Endocrinol and Diab. 6:163,1999.
177. Heiman, M. L., Sloop, K. W., Chen, Y. and J. F. Caro. Extension of Neuroendocrine Axes to Include Leptin. J. Anim. Sci. 77:33,1999.
178. Goldstein, D. J. and J. F. Caro. Genetics and Potential Treatments for Obesity. The Management of Eating Disorders, Chapter 18. Humana Press, Inc., 1999.
179. Ohannesian, J.P., Marco, C.C., Najm, P.S., Goldstein, B.J., Caro, J. F., and J.W. Kolaczynski. Small Weight Gain is not Associated with Development of Insulin Resistance in Healthy, Physically Active Individuals. Horm. Metab. Res. 31:323, 1999. 179.
180. Kolaczynski, J. W. and J. F. Caro. Insulin Resistance: Site of the Primary Defect or How the Current and the Emerging Therapies Work. J. Basic & Clin. Physiol. & Pharmacol.281, 1999.
181. Caro, J.F. Obesity. In: McGraw-Hill. Yearbook of Science & Technology, 2000.
182. Corominola, H., L.J. Conner, L.S. Beavers, R.A. Gadski, D. Johnson, J. Sluka, J.F. Caro and R. Rafaeloff-Phail. Identification of Novel Genes Differentially Expressed in Omental Fat of Obese and Obese Type 2 Diabetic Patients. Diabetes 50:2822, 2001
183. Caro, J. F. and M. Trautmann. Leptin: The Adipocyte Signal in the Control of Body Weight. In: Handbook of Experimental Pharmacology, 2000.
184. Dananberg, J. and J.F. Caro. Obesity. In: Endocrinology. L.J. DeGroot, (Ed.), W. B. Saunders, 2000.
185. Caro, J.F. and L.E. Stramm. Biochemical Defects of Insulin Action in Humans. In: Diabetes Mellitus. D. LeRoith, S.I. Taylor, and J.M. Olefsky, (Eds.), Lippincott-Ravin, 2000.
186. Statnick, M.A., L.S. Beavers, L.J. Conner, H. Corominola, D. Johnson, C.D. Hammond, R. Rafaeloff-Phael, T.Seng, T.Suter, J.P. Sluka, E. Ravussin R.A. Gadski, and J.F. Caro. Decreased Expression of apM1 in Omental and Subcutaneous Adipose Tissue of Humans with Type 2 Diabetes. Int. J. Exp. Diabetes Res., 2000.
187. Caro, J.F. and M.E. Trautmann. Leptin: The Adipocyte Signal in the Control of Body Weight. In: Obesity: Pathology and Therapy. T.G. Heffner and D.H. Lockwood, (Eds.), Springer-Verlag, 2000.
188. Caro, J.F., R.V. Considine. Handbook of Obesity, Chapter 59. G. Bray and C. Bouchard (Eds), M. Decker and Co., 2001
189. Rohner-Jeanrenaud, F., L. S. Craft, J. Bridwell, T. M. Suter, F. C. Tinsley, D. L. Smiley, D.R. Burkhart, M.A. Statnick, M.L. Heiman, E.R. Ravussin, and J.F. Caro. Chronic central CART infusion decreases body weight and increases lipid oxidation in lean and high fat fed obese rats. Int J Obes Relat Metab Disord. Feb; 26(2):143-9,2002.
191. Moyers, J.S. and Caro, J.F. Insulin Resistance – Emerging Therapies for Affect Sites.In Insulin Resistance and Insulin Resistance Syndrome, Frontiers in Animal Diabetes, editedby B.C. Hansen and E. Shafrir. pp 313-333, Taylor & Francis Publisher, NY 2003.
192. Caro, J.F. Health Implication, Definitions and Classification of Obesity. In: Endotext.com. 2004
193. Etgen, G.J., M.J. Prince, J.F. Caro. Peroxisome Proliferator-Activated Receptor Modulators. In: Diabetes Mellitu: A Fundamental and Clinical Text. D. LeRoith, S.I. Taylor, and J.M. Olefsky, (Eds.), Lippincott Williams & Wilkins, 2004..
194. Caro, J.F., R.V. Considine. Handbook of Obesity, Chapter 59. G. Bray and C. Bouchard (Eds.), M. Decker and Co., 2004
195. Caro, J.F. and Dananberg, J. Obesity: The Problem and its Management. In: Endocrinology. L.J. DeGroot, and J.L. Jameson (Ed). Elsevier, Saunders, 2005.
196. Serrano Rios, M. Caro, J. F., Carraro, C., Gutierrez Fuentes, J.A. Introduction In: The Metabolic Syndrome at the Beginning of the XXI Century A genetic and MolecularApproach. ELSEVIER. 2006
197. Peer Support Programmes in Diabetes. Advisor and Member of the Organization Committee. Report of WHO consultation, 5-7 November 2007. Publication WHO/CPM/08/01
198. Caro, J.F. On the Trail to Arrest the Progression of the Metabolic Syndrome. Endocrinol Nutr. 54 Supl 4: 37, 2007
199. Caro, J.F., Rosas, J. Diabetes and Depression: Initial Questions. Journal of ALAD, 16: 50, 2008
200. Considine, R. and Caro, J.F. Obesity: The Problem and its Management. In: Endocrinology. L.J. DeGroot, and J.L. Jameson (Ed). Elsevier, Saunders, 2010
201. Caro, J.F. and Fisher E. Editorial. A Solution Might be Within People with Diabetes Themselves. Family Medicine, Supp 1: i1, 2010

Abstracts Presented (Incomplete List)

1. Caro, J.F., A. Besarab, J.F. Burke, and J.A. Glennon. 1978. Propranolol: A possible role in the treatment of renal osteodystrophy. American College of Physicians Eastern Pennsylvania Regional Meeting.
2. Caro, J.F., J.A. Glennon, and H.L. Israel. 1978. Neuroendocrine studies in sarcoidosis 8th International Congress of Sarcoidosis, Cardiff.
3. Caro, J.F., and P.D. Woolf. 1979. Hyperprolactinemia diminishes pituitary LH reserve but no ovarian responsitivity to GnRH infusion. The Endocrine Society 61st Annual Meeting.
4. Besarab, A., J.F. Caro, B.U. Ihle, and J.F. Burke. 1979. Beta-adrenergic blockade and hyperparathyroidism in chronic renal failure. Clin. Res., Eastern Section.
4. Caro, J.F., and J.M. Amatruda. 1979. The effect of fasting on glucagon action and binding isolated rat hepatocytes. Clin. Res., Midwest Section.
5. Caro, J.F., and J.M. Amatruda. 1980. Insulin-mimickers down regulate the insulin receptor: Evidence for a post receptor mechanism. Amer. Diab. Assoc., 40th Annual Meeting, Diabetes 29:38A.
6. Caro, J.F., and J.M. Amatruda. 1980. Insulin receptor antibodies modulate insulin action and degradation independently of binding. The Endocrine Society 62nd Annual Meeting
7. Caro, J.F., J.M. Amatruda. 1980. Post receptor events regulate the insulin receptor. Amer. Diab. Assoc., 41st Annual Meeting, Diabetes 30:9A.
8. Caro, J.F., G. Muller, and J.A. Glennon. 1982. Insulin processing by the liver. Amer. Diab. Assoc., 42nd Annual Meeting, Diabetes 31:133A.
9. Kauffman, J.M., G. Muller, and J.F. Caro. 1982. Mechanism of insulin resistance in rat hepatocytes: a new model of chronic uremia. Amer. Diab. Assoc., 42nd Annual Meeting. Diabetes 31:124A.
10. Caro, J.F., F. Cecchin, and M. Sinha. 1983. Is cell glycosylation needed for insulin binding and post binding events? Amer. Diab. Assoc., 43rd Annual Meeting. Diabetes 32:32A.
11. Caro, J.F., and S. Lanza-Jacoby. 1983. Insulin resistance in uremia: the role of the liver. The Endocrine Society, 65th Annual Meeting.
12. Caro, J.F., F. Cecchin, F. Folli, and M. Sinha. 1983. Triiodothyronine-induced insulin resistance in primary cultures of rat hepatocytes. European Thyroid Association, XII Annual Meeting. Annales, d endocrinology, 44:87A.
13. Caro., J.F., F. Folli, M. Sinha, and D. Brancaccio. 1984. Insulin resistance in uremia: in vitro model to study mechanism(s) in the liver. Amer. Diab. Assoc. 44th Annual Meeting. Diabetes 38:138A.
14. Sinha, M.K., and J.F. Caro. 1984. Insulin mediator in serum? Recognition of an artifact. Amer. Diab. Assoc. 44th Annual Meeting. Diabetes 38:140A.
15. Caro, J.F., O. Ittoop, and M.K. Sinha. 1984. Tolazamide and glyburide but not ciglytazone enhance insulin action in the liver. 7th International Congress of Endocrinology
16. Caro, J.F., M.K. Sinha, M.L. McCaleb, G.B. Wish, and D.H. Lockwood. 1985. Insulin resistance in uremia is due to a post insulin receptor kinase defect(s). Clin. Res. 33:426A.
17. Sinha, M.K., O.Ittoop, and J.F. Caro. 1985. Enhanced insulin receptor kinase activity in a patient with extreme insulin resistance and acanthosis nigricans. Clin. Res. 33:444A.
18. Caro, J.F., O. Ittoop, W. Pories, R. Dudek, and M.K. Sinha. 1985. Insulin responsive human hepatocytes. Amer. Diab. Assoc. 45th Annual Meeting. Diabetes 34:50A.
19. Sinha, M.K., O. Ittoop, M. Jenquin, and J.F. Caro. 1985. Effect of down-regulation and tunicamycin on insulin receptor autophosphorylation and kinase activity. Amer. Diab. Assoc. 95th Annual Meeting. Diabetes 34:159A.
20. Dohm, G.L., J.F. Caro, and M.K. Sinha. 1985. Insulin receptors and insulin receptor protein kinase activity in muscle of endurance trained rats. Medicine and Science in Sport and Exercise 17:240.
21. Caro, J.F., F. Cecchin, F. Kasperek, M. Jenquin, O. Ittoop, and M.K. Sinha. 1985. Insulin resistance in uremia: insulin receptor kinase activity in liver and muscle is different. XII Congress of the International Diabetes Foundation.
22. Caro, J.F., G.L. Dohm, and M.K. Sinha. 1985. Insulin resistance in uremia: decreased hepatic fructose 2,6-bisphosphate. XXI Congress of the International Diabetes Federation.
23. Caro, J.F., W. Pories, O. Ittoop, M. Jenquin, H.D. Meelheim, E. Flickinger, J.F. Silverman, F. Thomas, M.K. Sinha. 1985. Mechanism of insulin resistance in isolated hepatocytes from morbidly obese patients with NIDDM. Int. J. of Obesity 9:A15.
24. Sinha, M.K., W. Pories, M. Jenquin, O. Ittoop, H.D. Meelheim, E. Flickinger, J.F. Caro. 1985. Down regulation of insulin receptors and insulin action in cultured adipocytes from morbidly obese patients with or without NIDDM. Int. J. of Obesity 9:A95.
25. Caro, J.F., M.K. Sinha, and I.D. Goldfine. 1986. Monoclonal antibodies to the human insulin receptor that activate glucose transport but not insulin receptor kinase activity. III International Symposium on Insulin Receptors and Insulin Action. Madrid, Spain.
26. Caro, J.F., O. Ittoop, W. Pories, D. Meelheim, and M.K. Sinha. 1986. Studies on the mechanism of insulin resistance in the liver from humans with Noninsulin-dependent Diabetes: insulin action and binding in isolated hepatocytes, insulin receptor structure and kinase activity. III International Symposium on Insulin Receptors and Insulin Action. Madrid, Spain
27. Dvornik, D., R. Gonzales, D. Hicks, T. Smith, S. Ryder, J.F. Mullane, P. Raskin, J. Rosenstock, P. Challis, J. Caro, and W. Fore. 1985. Effect of tolrestat on RBC sorbitol levels in subjects with diabetes mellitus. Diabetes Research and Clinical Practice. Supplement I:S146.
28. Silverman, J.F., D.J. Dabbs, K.F. O'Brien, H.T. Norris, and J. Caro. 1987. Liver pathology in morbid obesity. Laboratory Investigation. 56:IA.
29. Pories, W.J., J.F. Caro, E.G. Flickinger, H.D. Meelheim, and M.S. Swanson. 1987. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville gastric bypass operation. 107th Meeting of the American Surgical Association.
30. Caro, J.F., S.I. Taylor, O. Ittoop, S.M. Raju, and W.J. Pories. 1987. Endogenous substrates of insulin receptor kinase in human liver plasma membranes: defect(s) in NIDDM. The Endocrine Society.
31. Sinha, M.K., W.J. Pories, E. Flickinger, D. Meelheim, S. Atkinson, N.S. Sehgal, and J.F. Caro. 1987. Insulin worsens the insulin resistance of adipocytes in primary culture from obese and NIDDM subjects. The 69th Annual Meeting of the Endocrine Society, Indianapolis.
32. Caro, J.F., M.K. Sinha, S.M. Raju, O. Ittoop, W.J. Pories, D. Meelheim, E. Flickinger, and G.L. Dohm. 1987. Insulin receptors and insulin receptor kinase activity in human skeletal muscle from obese subjects with and without NIDDM. American Diabetes Association, 47th Scientific Sessions Meeting, Indianapolis
33. Forsayeth, J.R., J.F. Caro, M.K. Sinha, B.A. Maddux, and I.D. Goldfine. 1987. Monoclonal antibodies to the human insulin receptor activate glucose transport but not insulin receptor kinase activity. Clinical Research 35:622A.
34. Caro, J.F., S.M. Raju, M.K. Sinha, I.D., Goldfine, and G.L. Dohm. 1988. Heterogeneity of human liver, muscle, and adipose tissue insulin. Clinical Research 36:479A.
35. Caro, J.F., A. Rovira, J.J. Chen, N. Leggett, K. O'Brien, C. Sash, K. Parker, F. Thomas, and G. L. Dohm. 1988. Insulin resistance in the skeletal muscle of uremic patients is a post insulin receptor kinase defect(s). Clinical Research 36:479A.
36. Caro, J.F., J. Poulos, O. Ittoop, N. Mooney, and M.K. Sinha. 1988. Insulin-like growth factor I receptors in hepatocytes from human liver, human hepatoma and normal, regenerating and fetal rat liver. Clinical Research 36:479A.
37. Dohm, G.L., C.W. Elton, W. J. Pories, E.C. Flickinger, S.M. Atkinson, and J.F. Caro. 1988. Changes in glucose transport and insulin sensitivity of in vitro incubated human muscle from obese and diabetic subjects. The FASEB Journal, Vol. 2, No. 5.
38. Sinha, M.K., C. Buchanan, L. Martin, R. DiMarchi, and J.F. Caro. 1988. Insight into the mechanism of 16F-1 stimulated glucose transport in human fat cells. The Endocrinology Society Program and Abstracts, 70th Annual Meeting, 517.
39. Chen, J.J., N. Leggett, W. Pories, E. Flickinger, K. O'Brien, P. Khazanie, and J.F. Caro. 1988. Noninsulin dependent diabetes mellitus worsens the severe insulin resistance of morbid obesity. The Endocrinology Society Program and Abstracts, 70th Annual Meeting, 1105.
40. Thakkar, J.K., R. DiMarchi, and J.F. Caro. 1988. Insulin, IGF-I and IGF-II do not stimulate phosphatidylinositol-4, 5-biphosphate specific-phospholipase C in human liver. Diabetes Program 48th Annual Meeting, 114.
41. Sinha, M.K., C. Buchanan, L. Martin, R. DiMarchi, and J.F. Caro. 1988. Presence of IGF-II receptors and IGF-II stimulation of glucose metabolism in human adipocytes. Diabetes Program 48th Annual Meeting, 729.
42. O'Brien, K.F., T.C. Chen, T.C. Chenier, and J.F. Caro. 1988. Using oral glucose tolerance test to evaluate glucose uptake, insulin release, and resistance. Eastern North American Regional Biometrics Society, Boston, Massachusetts.
43. Pories, W.J., E.G. Flickenger, K.G. MacDonald, and J.F. Caro. October 1989. Long Term effect of the gastric bypass operation on weight, diabetes, hypertension, and mental health in the morbidly obese. Clinical Congress, American College of Surgeons, Atlanta, Georgia.
44. Thomas, F., W. Costellani, C. Sash, H. Daniel, L. Dabuey, P. Cunningham, A. Ferguson, and J.F. Caro. 1989. Studies of radioimmunescence reactive urinary insulin in humans. New Test for Diagnosis of Pancreas Rejection. First International Congress of Pancreatic and Islet Transplanting. Diabetes 38(Sup 1):253
45. Dunham, D., S. Marcuard, A. Hobbs, and J.F. Caro. 1989. Availability of insulin from total parenteral nutrition (TPN) solutions. 13th Clinical Congress Abstracts. JPEN 13(Supp)1:8S.
46. Caro, J.F., M.K. Sinha, and G.L. Dohm. Insulin Resistance. 1989. J. Cell Biochemistry (Supp 13E):224
47. Dohm, G.L., C.W. Elton, S.M. Raju, N. Mooney, R. Dimarchi, W.J. Pories, E.G. Flickinger, S.M. Atkinson, and J.F. Caro. 1989. IGF-I and IGF-II stimulated glucose transport in human skeletal muscle: IGF resistance in obesity and NIDDM. Diabetes, 49th Annual Meeting, 50A.
48. Sinha, M.K., C. Buchanan, C. Raineri-Maldonado, P. Khazanie, W.J. Pories, R. Dimarchi and J.F. Caro. IGF-I Stimulated glucose transport, IGF-I receptors and tyrosine kinase are not altered as noted for insulin in adipocytes from NIDDM patients. Diabetes, 49th Annual Meeting, 103A.
49. Elton, C.W., E.B. Tapscott, J.F. Caro, P.F. Pilch, W.J. Pories, S.M. Atkinson, and G.L. Dohm. 1989. "Effect of moderate obesity on glucose transport in human muscle." Int. J. Obes., 1989 Annual Meeting of the North American Association for the Socity of Obesity.
50. Caro, J.F., S.M. Raju, N. Leggett-Frazier, L. Roy, S. Long, and K. O'Brien. 1990. "Altered coupling of the insulin receptor with Gi protein in the liver from patients with NIDDM." ADA 50th Annual Meeting and Scientific Sessions.
51. Caro, J.F., M.K. Sinha and G.L. Dohm. Insulin resistance in obesity. 1990. Int. J. Obes. (Supp) 2:28.
52. Caro, J.F., M.K. Sinha, G.L. Dohm. July 1990. Alterations in insulin receptors and glucose transporters in obese and diabetic man. Fundamental and Clinical Pharmacology 4 (Supp)1:10S. Pathophysiology and Treatment of Diabetes Melllitus (Satellite Meeting of the Amsterdam XIth International Congress of Pharmacology), Montpellier, France
53. Marcuard, S.P., B. Dunham, M.K. Sinha, S.J. Raju, J.F. Caro., May 1991. Insulin binds to heparinin TPN solutions. American Gastroenterological Association, New Orleans, Louisiana.
54. Caro, J.F., M.K. Sinha, W.J. Pories, H.A. Barakat, P.G. Khazanie, G.L. Dohm. 1991. J Cell Bioch. (Supp. 15B):13, CA023.
55. Burguera B., R.K. Stanzak, L.J. Slieker, W.F. Health, N. Leggett-Frazier, L. Roy, S. Long, and J.F. Caro. 1991. Is the low level of GLUT-2 gene expression present in impaired glucose tolerant patients (IGT) preventing or inducing non-insulin dependent diabetes mellitus (NIDDM)? 73rd Annual Meeting, The Endocrine Society, #1765, pg. 472
56. Friedman, J.E., W.J. Pories, N. Leggett-Frazier, L.L. Roy, S.D. Long, J.F. Caro, and G.L Dohm. 1991. Evidence for decreased insulin sensitive glucose transporters (GLUT 4) in skeletal muscle for a large sample of obese and obese-NIDDM patients. ADA 51st Annual Meeting and Scientific Sessions. Diabetes #630.
57. Sinha, M.K., T. Madigan, G. Cooper, and J.F. Caro. 1991. Effect of amylin and calcitonin gene related peptide-1 (CGRP-1) on glucose transport in isolated adipocytes from lean, obese and NIDDM patients. ADA 51st Annual Meeting and Scientific Sessions. Diabetes #955, pg. 239A
58. Barakat, H.A., K. O'Brien, S. Long, P. Khazanie, W. Pories, and J. Caro. 1991. Coronary artery disease risk factors in morbidly obese women with normal glucose tolerance. ADA 51st Annual Meeting and Scientific Sessions. Diabetes #1711, pg. 429A.
59. MacDonald, K.G., W.J. Pories, C.A. Moore, N. Leggett-Frazier, C. Jone, S. Long, E. Morgan, L. Roy, J.F. Caro. 1992. The reversal of diabetes mellitus (DM) with gastric bypass: correlation of duration of diabetes with glucose response and insulin release. Annual Meeting, American Society for Bariatric Surgery, New Orleans.
60. Ravindra, R., J.F. Caro. 1992. Insulin stimulates GDP release from G proteins in the rat and human liver. 74th Annual Meeting, The Endocrine Society, Texas, #23, pg. 57.
61. Long, S.D., K. O'Brien, M. Swanson, K. MacDonald, N. Frazier, W.J. Pories, J.F.Caro. 1992. Weight loss prevents the progression of impaired glucose tolerance to non-insulin dependent diabetes mellitus: A ten year longitudinal study. 52nd Annual Meeting, Diabetes #266. pg. 72A
62. Ravindra, R. and Caro, J. 1993. Effect of Glucagon on GDP release from G Proteins in the rat liver plasma membranes. 75th Annual Meeting, The Endocrine Society #526. pg. 182.
63. Moore, J.H., Kolaczynski, J.W., Morales, L.M., Considine, R.V., Pietrzkowski, Z., Noto, P.F. and Caro, J.F. 1993. Viability of fat obtained by syringe suction lipectomy: Effects of local anesthesia with Lidocaine. The Lipoplasty Society of North America, Inc., Annual Meeting, New Orleans
64. Considine, R.V., Allen, L., Nyce, M., Noto, P., Triester, S., Morales, L.M. and Caro, J.F. 1994. Membrane protein kinase C is increased in NIDDM liver. Studies of PKC isozyme distribution in both humans and a rat model. 54th Annual Meeting, American Diabetes Association, New Orleans.
65. Swanson, S., Long, E., Smith, K., MacDonald, G., Dohm, N., Frazier, J. Caro, J and Pories W. 1994. Early gastric bypass provides better control of NIDDM in the morbidly obese. 7th ICO Satellite Symposium, Surgical Treatment of Obesity, Montreal, Quebec
66. Koda, J.E., Fineman, M.S., O.G. Kolterman, and Caro, J.F. 1995. 24 Hour Plasma Amylin Profiles are Elevated in IGT Subjects vs. Normal Controls. 55th Annual Meeting and Scientific Sessions American Diabetes Association, Atlanta, Georgia, Diabetes #876, pg. 45A.
67. Spiegelman, B.M., P. Arner, J.F. Caro, R.L. Atkinson and G.S. Hotamisligil. 1995. Elevation of Adipose Tissue Expression of TNFα and TNF Receptors in Human Obesity and Insulin Resistance. 55th Annual Meeting and Scientific Sessions American Diabetes Association, Attanta, Georgia, Diabetes #164, pg. 45A.
68. Considine, R.V., E.L. Considine, C.J. Williams, M. Nyce, S.A. Magosin, T.L. Bauer, E.L. Rosato, J. Colberg and J.F. Caro. 1995. Ob Gene Expression is Increased in Adipocytes from Obese Humans. 55th Annual Meeting and Scientific Sessions, Atlanta, Georgia, Diabetes #739, pg. 202A..
69. Heini, A.F., R.V. Considine, J.F. Caro, H. Schneider, and R.L. Weinsier. 1996. The Effect of a Hydrolyzed Guar Fiber on Fasting and Postprandial Glucose Metabolism, Cholecystokinin, Leptin and Satiety. XVIII ESPEN Congress, Geneva, Switzerland.
70. Heini, A.F., C. Lara-Castro, R.V. Considine, J.F. Caro, and R. L. Weinsier. 1996. Leptin and Satiety in obese women. XVIII ESPEN Congress, Geneva, Switzerland
71. Schoeller, D.A., Cella, L. Kessler, Sinha, M., and Caro, J.F. 1996. Entrainment of the Diurnal Variation in Plasma Leptin Levels. North American Association for the Study of Obesity.Breckenridge, Colorado
72. Israel, R.G., M.S. Hickey, R.V. Considine, T.L. Mahar, M.R. McCammmon, G.L. Tyndall, J.A. Houmard, and J. F. Caro. 1996. Leptin is Related to Fat Mass in Highly Trained Endurance Runners. North American Association for the Study of Obesity. Breckendridge, Colorado
73. Wauters, M., R. Considine, C. Van Broeckhoven, I. De Leeuw, J. Caro, L. Van Gaal. 1996. Associations of Leptin with Body Composition are Influenced by Apoe Polymorphism in NIDDM Patients. North American Association for the Study of Obesity. Breckenridge, Colorado
74. Letiexhe, M.R., A. J. Scheen, J.F. Caro and P.J. Lefebvre. 1997. Post-Gastroplasty Recovery of Ideal Body Weight Normalizes Serum Leptin Levels of Obese Women. Diabetologia. 40:A263.
75. Letiexhe, M.R., A.J. Scheen, F. Sodoyez-Goffaux, J.F. Caro and P.J. Lefebvre. 1997. Relationships between Basal Plasma Leptin, Fasting Total or True Insulin Levels, and Insulin Sensitivity Index S1 in Lean, Oese and Post-Obese Females. International Journal of Obesity. 21:(Suppl.2). S101
76. Zhang, P.L., J.D. Liang, G.E. Sandusky, B. Burguera, R,V. Considine, T.M. Hyde, H.M. Hsiung, P.R. Sankhavaran, M.A. Esterman, E. Maratos-Flier and J.F. Caro. 1998. Hypothalamic MCH mRNA and Protein are Increased in Human Obesity. Genetic and Molecular Basis of Obesity, Satellite Symposium of the 8 th International Congress on Obesity. Paris, France.
77. Statnick, M.A., P.L. Zhang, C. Hammond, L. Beavers, L.J. Conner, D. Johnson, T.M. Suter, R. Gadski and J.F. Caro, 1998. Expression of SOCS3, An Inhibitor of Leptin Signaling, is not Altered in the anterior Hypothalamus of Obese Humans. Genetic and Molecular Basis of Obesity, Satellite Symposium of the 8 th International Congress on Obesity. Paris, France.
78. Woodworth, J.R., D.C. Howey, R.R. Bowsher, M.E. Trautmann and J.F. Caro. 1998. The Pharmacokinetics and Acute Effects of LY355101, a Novel Anti-obesity Protein, in Healthy Volunteers. Genetics and Molecular Basis of Obesity, Satellite Symposium